Page last updated: 2024-11-13

cyclin d1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72998476
MeSH IDM0029612

Synonyms (1)

Synonym
cyclin d1

Research Excerpts

Overview

Cyclin D1 is a protein that can increase the proliferation of cancer cells. It forms a complex with CDK4/6 to regulate G1/S transition during cell cycle progression.

ExcerptReferenceRelevance
"Cyclin D1b is a highly oncogenic variant of cyclin D1."( Cyclin D1b induces changes in the macrophage phenotype resulting in promotion of tumor metastasis.
Han, L; Hu, Y; Liu, Y; Wang, Y; Wu, F; Xiang, L; Yao, X, 2021
)
2.79
"Cyclin D1 is a regulatory subunit of -Cyclin Dependent Kinases 4 and 6 (CDK4/6) and regulates progression from G1 to S phase of the cell cycle. "( Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss.
Avril, S; Diehl, JA; Koivisto, C; Leone, G; Phillips-Mason, P; Tarallo, V; Yoshida, A, 2022
)
2.48
"Cyclin D1 is a gene of cell cycle regulation."( Immunohistochemical Overexpression of Cyclin D1 in Tunisian Invasive Breast Carcinoma Women.
Bouzidi, L; Feki, J; Gouiaa, N; Graja, S; Kallel, R; Makni, S; Mellouli, M; Sellami-Boudawara, T, 2022
)
1.71
"Cyclin D1 (CCND1) is a critical regulator of cell proliferation and its overexpression has been linked to the development and progression of several malignancies. "( Regulation of Cyclin D1 Degradation by Ubiquitin-Specific Protease 27X Is Critical for Cancer Cell Proliferation and Tumor Growth.
Alam, S; Atanassov, BS; Feigin, ME; Venkat, S; Zunic, A, 2022
)
2.52
"Cyclin D1 is a protein involved in cell cycle regulation from G1 phase to S phase."( Immunohistochemical Expression Of Cyclind1 In Conventional Squamous Cell Carcinomaof Oral Cavity.
Ahmad, A; Azmat, H; Firidi, J; Khadija, S; Rauf, M; Shahab, S,
)
0.85
"Cyclin D1 is a protein that can increase the proliferation of cancer cells. "( Cyclin D1 expression, clinicopathological characteristics, and 2-year survival rate of gastric cancer in Cipto Mangunkusumo General Hospital.
Cahyanur, R; Rahadiani, N; Utari, AP, 2023
)
3.8
"Cyclin D1 is a key regulator of cell cycle progression, which forms a complex with CDK4/6 to regulate G1/S transition during cell cycle progression. "( Multiple cullin-associated E3 ligases regulate cyclin D1 protein stability.
Chen, D; Lu, K; Tong, L; Wei, G; Xiao, G; Zhang, M, 2023
)
2.61
"Cyclin D1 (CCND1) is a well-known proliferation promoter that accelerates G1/S transition in cancer. "( circRNA circ-CCND1 promotes the proliferation of laryngeal squamous cell carcinoma through elevating CCND1 expression via interacting with HuR and miR-646.
Li, J; Tai, Y; Wan, B; Zang, Y, 2020
)
2
"Cyclin D1 is a protein encoded by the CCND1 gene, located on 11q13 chromosome, which is a key component of the physiological regulation of the cell cycle. "( An update on the implications of cyclin D1 in melanomas.
Ayén, Á; González-Moles, MÁ; González-Ruiz, I; González-Ruiz, L; Ramos-García, P; Ruiz-Ávila, I, 2020
)
2.28
"Cyclin D1 is a key regulatory factor of the G1 to S transition during cell cycle progression. "( A Cyclin D1-Specific Single-Chain Variable Fragment Antibody that Inhibits HepG2 Cell Growth and Proliferation.
Cao, Y; Cheng, C; Jiang, D; Li, C; Li, G; Tang, W; Wang, S; Wu, Y; Yang, F; Zhang, Y; Zhao, J; Zhao, L; Zhu, X, 2020
)
2.72
"Cyclin D1 is an essential part of oncogenic transformation. "( Upregulation of cyclin D1 can act as an independent prognostic marker for longer survival time in human nasopharyngeal carcinoma.
Chen, M; Chen, Y; Fan, S; Huang, D; Li, G; Li, X; Liu, Q; Liu, Y; Wang, Z; Xiong, W; Zhang, W, 2020
)
2.35
"Cyclin D1 is a protein involved in the cell cycle, which will stimulate proliferation."( The Difference in the Cyclin D1 Expression in Advanced Stage Nasopharyngeal Cancer based on Treatment Response: A Retrospective Cohort Study.
Abdullah, M; Cahyanur, R; Irawan, C; Lisnawati, L; Yunus, RE, 2020
)
1.59
"Cyclin D1 is a major cell-cycle regulator and also regulates transcription, but the impact of cyclin D1-mediated transcriptional dysregulation on MCL pathogenesis remains poorly understood."( A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma.
Albero, R; Beà, S; Campo, E; Capdevila, C; Castellano, G; Clot, G; Demajo, S; Enjuanes, A; Giné, E; Jaffe, ES; Jares, P; López-Guillermo, A; Nadeu, F; Navarro, A; Ott, G; Pinyol, M; Rimsza, LM; Rosenwald, A; Scott, DW; Staudt, LM, 2021
)
2.06
"Cyclin D1 is an essential regulator of the G1-S cell-cycle transition and is overexpressed in many cancers. "( PARP14 regulates cyclin D1 expression to promote cell-cycle progression.
Moldovan, GL; Nicolae, CM; O'Connor, MJ; Thakar, T, 2021
)
2.4
"Cyclin D1 is a proto-oncogene and is one of the major regulators of Wnt signaling pathway, and its overexpression has been detected in various types of cancers including hepatocellular carcinoma."( Bioinformatics prediction and experimental validation of microRNA-20a targeting Cyclin D1 in hepatocellular carcinoma.
Ahsani, Z; Karimkhanloo, H; Mohammadi-Yeganeh, S; Paryan, M, 2017
)
1.4
"Cyclin D1 (CycD1) is a cell cycle regulator protein."( The prognostic significance of cyclin D1 expression in patients with triple-negative breast cancer.
Akder Sari, A; Akyol, M; Alacacioglu, A; Bolat Kucukzeybek, B; Kucukzeybek, Y; Oktay Tarhan, M; Vedat Bayoglu, I; Yigit, S,
)
1.14
"Cyclin D1 is a critical regulator of cell cycle progression and works at the G1 to S-phase transition. "(
Cao, L; Li, J; Wu, M; Zhang, P, 2017
)
1.9
"Cyclin D1 (CCND1) is a core cell cycle regulator and is frequently overexpressed in human cancers, often via amplification, translocation or post-transcription regulation. "( Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas.
Lin, DI; Xu, J, 2018
)
2.24
"Cyclin D1 is an oncogene frequently overexpressed in human cancers that has a dual function as cell cycle and transcriptional regulator, although the latter is widely unexplored. "( Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms.
Albero, R; Beà, S; Campo, E; Capdevila, C; Castellano, G; Clot, G; Colomer, D; Demajo, S; Enjuanes, A; García, N; Jares, P; Karube, K; López-Guerra, M; Martin-Subero, JI; Pinyol, M; Shimada, M; Suárez-Cisneros, H, 2018
)
3.37
"Cyclin D1 is a critical modulator of cell cycle activation and upregulation of Cyclin D1 in neurons contributes to the pathology associated with traumatic brain injury (TBI)."( Activation of cyclin D1 affects mitochondrial mass following traumatic brain injury.
Gupta, R; Saha, P; Sen, N; Sen, T, 2018
)
1.56
"Cyclin D1 is a sensitive but not specific immunohistochemical marker for CCSK and many other pediatric renal malignant neoplasms as well as for neuroblastoma. "( Expression of cyclin D1 in clear cell sarcoma of kidney. Is it useful in differentiating it from its histological mimics?
Abdul-Ghafar, J; Ahmad, Z; Ahmed, A; Minhas, K; Uddin, N, 2019
)
2.32
"Cyclin D1 is an important molecule in the transition from G1 to S phase of the cell cycle, and is frequently deregulated in cancers."( Downregulation of TCEAL7 expression induces CCND1 expression in non-small cell lung cancer.
Bulut, P; Buyru, N; Dalay, N; Ersen, E; Orhan, C, 2019
)
1.24
"Cyclin D1 is a component of the core cell-cycle machinery and is frequently overexpressed in breast cancer. "( Cooperation between Dmp1 loss and cyclin D1 overexpression in breast cancer.
Fry, EA; Inoue, K; Kulik, G; Mott, RT; Sui, G; Taneja, P; Zhu, S, 2013
)
2.11
"Cyclin D1 is a pivotal regulatory protein involved in cell cycle progression, and its depressed expression correlates with cell cycle prolongation or arrested at the G1/S transition."( The HTLV-1 HBZ protein inhibits cyclin D1 expression through interacting with the cellular transcription factor CREB.
Dong, Z; Jin, J; Li, M; Li, P; Ma, Y; Wang, N; Wang, Y; Zang, W; Zhao, G; Zheng, S, 2013
)
1.39
"Cyclin D1 is a key regulatory protein, which regulates cell cycle progression from G1 to S phase."( Peculiarities of cyclin D1 expression in reproductive and menopausal women with cervical hyperkeratosis.
Burkadze, GM; Chogovadze, NK; Dzhugeli, MK; Kachechiladze, MG, 2013
)
1.45
"Cyclin D1 was found to be a significant independent prognostic factor of lymph node metastasis (p = 0.000)."( Prognostic significance of cyclin D1 and E-cadherin expression in laryngeal squamous cell carcinoma.
Ahmed, RA; Hamed, RH; Shawky, Ael-A, 2014
)
1.42
"Cyclin D1 is an important positive regulator of the G1/S phase of the cell cycle. "( A cyclin D1 (CCND1) gene polymorphism contributes to susceptibility to papillary thyroid cancer in the Turkish population.
Aytekin, A; Aytekin, T; Borazan, E; Gokalp, MA; Maralcan, G; Ozen, D; Yilmaz, L, 2014
)
2.57
"Cyclin D1 is a cell cycle regulatory gene emerging as a potentially significant oncogene in invasive breast cancers. "( Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters.
Ananthamurthy, A; Ravikumar, G,
)
3.02
"Cyclin D1 is an important regulator protein for the G1-S cell cycle phase transition. "( Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry.
Bachmann, K; Bockhorn, M; El Gammal, AT; Hinsch, A; Izbicki, JR; Mann, O; Nentwich, MF; Neumann, A; Perez, D; Vashist, Y, 2015
)
3.3
"Cyclin D1 is a highly sensitive marker in differentiating LSCC from LD or HLM."( Clinical significance of Cyclin D1, FGF3 and p21 protein expression in laryngeal squamous cell carcinoma.
Arsenijevic, NN; Jovanovic, IP; Pejnovic, NN; Radosavljevic, GD; Simovic-Markovic, BJ; Stefanovic, SM; Stojanovic, SP,
)
1.16
"Cyclin D1 is an important molecular driver of human breast cancer but better understanding of its oncogenic mechanisms is needed, especially to enhance efforts in targeted therapeutics. "( Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis.
Addya, S; Arnold, A; Cardiff, RD; Casimiro, MC; Crosariol, M; Dampier, W; Di Sante, G; Ertel, A; Fortina, P; Knudsen, ES; Li, Z; Lisanti, MP; Loro, E; Papanikolaou, A; Pestell, RG; Saria, EA; Tozeren, A; Wang, C; Yu, Z, 2015
)
2.16
"Cyclin D1 (CCND1) is a key protein involved in cell-cycle regulation, and the CCND1 G870A polymorphism is associated with many types of malignancy. "( Cyclin D1 G870A gene polymorphism and risk of leukemia and hepatocellular carcinoma: a meta-analysis.
Dong, YL; He, HR; Lu, J; Ren, XD; Wang, MY; Zhang, L; Zhao, Y, 2015
)
3.3
"Cyclin D1 is an important cell cycle regulator implicated in the pathogenesis of many cancer types. "( Cyclin D1 G870A polymorphism is associated with an increased risk of multiple myeloma.
Fang, Z; Han, M; Huang, Y; Su, R; Wang, S, 2015
)
3.3
"Cyclin D1 (CCND1) is a β-catenin target gene."( Overexpression of cyclin D1 induces the reprogramming of differentiated epidermal cells into stem cell-like cells.
Fu, X; Huang, J; Li, H; Li, L; Li, Y; Ma, K; Sun, M; Yang, L; Zhang, C; Zhao, A, 2016
)
1.49
"Cyclin D1 is an important regulatory protein in cell cycle progression and is overexpressed in many cancer cells. "( Damnacanthal and its nanoformulation exhibit anti-cancer activity via cyclin D1 down-regulation.
Baek, SJ; Gritsanapan, W; Rojanapanthu, P; Silva, G; Sukamporn, P; Zhang, X, 2016
)
2.11
"Cyclin D1 (Ccnd1) is a proto-oncogen amplified in many different cancers and nuclear accumulation of Ccnd1 is a characteristic of tumor cells. "( Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer.
Castelblanco, E; Cemeli, T; Dolcet, X; Felip, I; Fernández-Hernández, R; Ferrezuelo, F; Fusté, NP; Garí, E; Gatius, S; Matias-Guiu, X; Pallarés, J; Pedraza, N; Santacana, M; Tarres, M; Valls, J, 2016
)
2.16
"Cyclin D1 (CyD1) is a cell cycleregulatory molecule, up-regulated at sites of inflammation in several tissues."( Cyclin D1 Gene Silencing by siRNA in Ex Vivo Human Tissue Cultures.
Barba, AA; Bochicchio, S; Carrizzo, A; Ciacci, C; Crescenzo, VD; Lamberti, G; Piazza, O; Russo, I; Vecchione, C; Zeppa, P, 2017
)
2.62
"Cyclin D1 is a cell cycle protein that promotes proliferation by mediating progression through key checkpoints in G1 phase. "( Cyclin D1 represses peroxisome proliferator-activated receptor alpha and inhibits fatty acid oxidation.
Albrecht, JH; Becker, JR; Hanse, EA; Hendrickson, AM; Kamarajugadda, S; Mashek, DG; Mashek, MT; Mullany, LK, 2016
)
3.32
"Cyclin D1 is an important regulator of the cell cycle and overexpression of this protein by immunohistochemistry is characteristically seen in mantle cell lymphoma and other B-cell neoplasms. "( Cyclin D1 expression in peripheral T-cell lymphomas.
Bedell, VH; Chen, YY; Feldman, AL; Herrera, AF; Kim, YS; Murata-Collins, JL; Nathwani, BN; Song, JY; Song, L; Tadros, R; Venkataraman, G; Weisenburger, DD, 2016
)
3.32
"Cyclin D1 is a protein required for progression through the G1 phase of the cell cycle and a known downstream target of β -catenin."( CXCR7 Participates in CXCL12-mediated Cell Cycle and Proliferation Regulation in Mouse Neural Progenitor Cells.
Huang, Y; Qiu, L; Wang, Y; Xu, P; Zhang, M; Zheng, JC, 2016
)
1.16
"Cyclin D1, therefore, serves as a transducer of v-Src-mediated induction of Trop2 ICD by enhancing abundance of the Trop2 proteolytic activation complex."( v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1.
Andò, S; Casimiro, MC; Deng, S; Di Rocco, A; Di Sante, G; Ertel, A; Fatatis, A; Gomella, LG; Hawkins, A; Jiao, X; Ju, X; Languino, LR; Li, Z; Lisanti, MP; Pestell, RG; Stoyanova, T; Zhan, T, 2016
)
1.4
"Cyclin D1 is a predictive biomarker for occult nodal metastases in early FOM cancers. "( Amplification and protein overexpression of cyclin D1: Predictor of occult nodal metastasis in early oral cancer.
Boeve, K; Koole, R; Noorlag, R; Peeters, TL; Schuuring, E; van Es, RJ; Willems, SM; Witjes, MJ, 2017
)
2.16
"As cyclin D1 is a regulatory subunit of cyclin-dependent kinases CDK4 and CDK6 and is required for the cells to progress through the G1 phase of the cell cycle, overexpression of cyclin D1 will likely promote cells into cell cycle."( Chronic myelogenous leukemia with acquired t(11;14)(q13;q32) CCND1-IGH: A case report and literature review.
Khalili, P; Manda-Mapalo, MT; Quintana, D; Rabinowitz, I; Zhang, QY, 2016
)
0.95
"Cyclin D1 (CCND1) is a key regulatory protein, playing a critical role in the transition from G1 to S phase of the cell cycle. "( Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population.
Chander, SR; Indu, G; Pushpinder, K; Satinder, K; Veena, J, 2008
)
3.23
"Cyclin D1 (CCND1) is a regulatory protein involved in the cell cycle of both normal and neoplastic cells. "( GG genotype of cyclin D1 G870A polymorphism is associated with non-cardiac gastric cancer in a high-risk region of China.
Chang, X; Dai, F; Gong, J; Hao, Z; Jia, A; Li, Y; Yu, B, 2008
)
2.14
"Cyclin D1 detection is a promising approach for the quantitative MRD monitoring in MCL patients, and the individual monitoring of the cyclin D1 dynamics represents a suitable indicator of the disease course."( Quantitative monitoring of cyclin D1 expression: a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma.
Brizova, H; Kalinova, M; Kodet, R; Krskova, L; Mrhalova, M, 2008
)
1.36
"Cyclin D1b is an alternative transcript of the cyclin D1 gene (CCND1) expressed in human tumors. "( Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b).
Benavides, F; Blando, J; Cardenas, K; Conti, CJ; Johnson, DG; Knudsen, ES; Perez, C; Richie, E; Rodriguez-Puebla, ML; Rojas, P; Senderowicz, AM, 2009
)
2.01
"Cyclin D1 is a well-known cell cycle regulator. "( Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity.
Chen, W; Yang, X; Zhang, P; Zhang, Z; Zhou, X, 2009
)
2.16
"Cyclin D1 (CCND1) is an important cell cycle regulator that is considered to be a downstream target of beta-catenin."( Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis.
Chen, X; Ho, C; Jones, KD; Lam, ET; Lee, SA; Macias, E; Patil, MA; Rodriguez-Puebla, M; Xu, C, 2009
)
1.51
"Cyclin D1 (CCND1) is a regulatory protein involved in the cell cycle. "( Cyclin D1 A870G polymorphism in Brazilian colorectal cancer patients.
da Silva, ID; de Lima, JM; de Souza, LG; Forones, NM, 2008
)
3.23
"Cyclin D1 which functions as a mitogenic sensor and allosteric activator of CDK4/6, is one of the more frequently altered cell cycle regulators in cancers."( Nuclear cyclin D1: an oncogenic driver in human cancer.
Diehl, JA; Kim, JK, 2009
)
1.51
"Cyclin D1 is an important cell-cycle regulator that drives the cell cycle from the G1 phase to the S phase. "( Relations between cyclin D1 and chromosome 11 in thyroid carcinoma: analysis by dual stain using FISH and immunostaining method.
Jikuzono, T; Shimizu, K; Tenjin, T, 2009
)
2.13
"Cyclin D1 is a key mediator of cell cycle progression in hepatocytes, and transient expression of this protein is sufficient to promote robust proliferation of these cells in vivo."( Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo.
Albrecht, JH; Anttila, CK; Berthet, C; Crary, GS; Goggin, MM; Hanse, EA; Kaldis, P; Kuriyama, R; Mullany, LK; Nelsen, CJ, 2009
)
1.29
"Cyclin D1 is a prominent oncogene in epithelial tumours."( Enhanced mRNA cap methylation increases cyclin D1 expression and promotes cell transformation.
Cowling, VH, 2010
)
1.35
"Cyclin D1 is a key regulator of cell proliferation and its expression is subject to both transcriptional and post-transcriptional regulation. "( Regulation of cyclin D1 gene expression.
Koh, LF; Perkins, ND; Witzel, II, 2010
)
2.16
"Cyclin D1 is a pivotal regulator of cell cycle progression, and increased expression strongly correlates with malignant transformation."( The HTLV-1 tax protein cooperates with phosphorylated CREB, TORC2 and p300 to activate CRE-dependent cyclin D1 transcription.
Egan, DI; Geiger, TR; Kim, YM; Nyborg, JK; Sharma, N, 2010
)
1.3
"Cyclin D1 is a cell cycle control protein that plays an important role in regenerating liver and many types of cancer. "( Cyclin D1 regulates hepatic estrogen and androgen metabolism.
Albrecht, JH; Anttila, C; Blomquist, CH; Delvoux, B; Hanse, EA; Mason, JI; Mullany, LK; Romano, A, 2010
)
3.25
"Cyclin D1 is a breast cancer oncogene whose amplification is linked to poor prognosis in estrogen and progesterone receptor-positive breast cancers."( Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression.
Brisken, C; Chen, L; Li, C; Lynch, MC; Schmidt, EV; Yang, C, 2010
)
2.52
"Cyclin D1 gene (CCND1) is a critical mitogen-regulated cell-cycle control element whose transcriptional modulation plays a crucial role in breast cancer growth and progression. "( Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.
Andò, S; Capparelli, C; Casaburi, I; Catalano, S; Garofalo, C; Giordano, C; Giordano, F; Lanzino, M; Maggiolini, M; Morelli, C; Sisci, D, 2010
)
2.16
"Cyclin D1 is a known substrate of polyubiquitination complex SKP1/CUL1/F-box (SCF), and our studies show that Cdc27 directs cyclin D1 to alternative degradation by APC/C."( C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression.
Balamurugan, K; Dowdy, SF; Huang, AM; Pawar, SA; Sarkar, TR; Sharan, S; Sterneck, E; Wang, J; Zhang, Y, 2010
)
1.4
"Cyclin D1 (CCND1) is a key regulatory protein in the G1/S checkpoint of the cell cycle. "( CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis.
Fu, S; Han, S; Ni, J; Wang, M; Zhang, Z; Zhou, D, 2011
)
1.81
"Cyclin D1 is a mediator of cell-cycle control that is frequently overexpressed in primary ductal breast carcinomas, but its role is controversial. "( Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.
Abramson, VG; Demichele, A; Diehl, A; Feldman, M; McNally, S; Mies, C; Sherman, L; Troxel, AB; Wang, Y, 2010
)
3.25
"Cyclin D1 (CCND1) is a key protein in regulation of cell cycle at the G1-to-S transition phase and is essential for regulation of cell proliferation, differentiation, and transcriptional control. "( Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer.
Gu, X; Shao, J; Wang, M; Yuan, L; Zhang, Z; Zhu, Q, 2010
)
3.25
"cyclin D1 is a member of the cyclin family, and it has been proven that it plaied an important role in tumorigenesis, invasion and metastasis. "( The relationships between cyclin D1 expression and prognosis of non-small cell lung cancer.
Song, Y; Wang, Q; Yu, L; Zhan, P; Zhu, J, 2010
)
2.1
"cyclin D1 expression is an independent prognosis factor for postoperative patient in stage I, II NSCLCs."( The relationships between cyclin D1 expression and prognosis of non-small cell lung cancer.
Song, Y; Wang, Q; Yu, L; Zhan, P; Zhu, J, 2010
)
2.1
"Cyclin D1 is a cell cycle regulatory protein that acts at the G1-S transition, following its binding to and activation by the cyclin-dependent kinases 4 or 6. "( Cyclin D1 inhibits mitochondrial activity in B cells.
Roussel, M; Sola, B; Tchakarska, G; Troussard, X, 2011
)
3.25
"Cyclin D1/Cdk4 is a critical target of the AKT survival signaling pathway responsible for tumor radioresistance. "( Targeting the AKT/GSK3β/cyclin D1/Cdk4 survival signaling pathway for eradication of tumor radioresistance acquired by fractionated radiotherapy.
Fukumoto, M; Kakuda, S; Kuwahara, Y; Ochiai, Y; Shimura, T; Takai, Y, 2011
)
2.12
"Cyclin D1 is a component of the core cell cycle machinery. "( A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.
Becks, L; Bienvenu, F; Clark, AB; Correll, M; Elias, JE; Goswami, T; Gygi, SP; Hu, Y; Jirawatnotai, S; Kunkel, TA; Livingston, DM; Michowski, W; Quackenbush, J; Sicinski, P; van Harn, T; Wang, YE; Xia, B; Zagozdzon, A, 2011
)
2.16
"Cyclin D1 (CCND1) is a known cell cycle regulator whose overexpression is a hallmark of mantle cell lymphoma (MCL). "( Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines.
Alluin, JV; Chen, RW; Chomchan, P; Forman, SJ; Gaur, S; Honegger, A; Rossi, JJ; Tiemann, K; Yun, Y, 2011
)
2.09
"Cyclin D1 (CD1) is a key modulator of CCA and is upregulated in neurons and microglia following traumatic brain injury (TBI)."( Cyclin D1 gene ablation confers neuroprotection in traumatic brain injury.
Byrnes, KR; Cabatbat, RM; Faden, AI; Hanscom, M; Kabadi, SV; Loane, DJ; Stoica, BA; Tan, MT, 2012
)
2.54
"Cyclin D1 is a well-characterised cell cycle regulator with established oncogenic capabilities. "( Cyclin D1, Id1 and EMT in breast cancer.
Landberg, G; Lehn, S; Lundgren, KL; Sims, AH; Tobin, NP, 2011
)
3.25
"Cyclin D1 is a key regulator of the cell cycle that is over expressed in more than half of breast cancer patients. "( The Discodermia calyx toxin calyculin a enhances cyclin D1 phosphorylation and degradation, and arrests cell cycle progression in human breast cancer cells.
Brautigan, DL; Edelson, JR, 2011
)
2.07
"Cyclin D1 is a critical regulator of the G 1 phase of the cell cycle and is regarded as key to initiating cell proliferation."( Evidence for cell cycle suppression and microRNA regulation of cyclin D1 during anoxia exposure in turtles.
Biggar, KK; Storey, KB, 2012
)
1.34
"Cyclin D1 is a major downstream target of PRL in lobuloalveolar development during pregnancy and is amplified and/or overexpressed in many breast carcinomas."( Prolactin promotes mammary pathogenesis independently from cyclin D1.
Arendt, LM; Asher, JM; O'Leary, KA; Rugowski, DE; Schuler, LA, 2012
)
1.34
"Cyclin D1 is an important cell cycle regulatory proteins, which is a functional target of Slug in the regulation of cell growth of prostate cancer cells. "( Slug regulates Cyclin D1 expression by ubiquitin-proteasome pathway in prostate cancer cells.
Ding, GX; Ding, Q; Feng, CC; Jiang, HW; Liu, J; Xu, JF, 2012
)
2.17
"Cyclin D1b is a splice variant of the cell cycle regulator cyclin D1 and is known to harbor divergent and highly oncogenic functions in human cancer. "( Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.
Augello, MA; Birbe, R; Burd, CJ; Dean, JL; Ertel, A; Fatatis, A; Feng, FY; Frigo, DE; Han, S; Jernigan, DL; Knudsen, KE; Magee, MS; McDonnell, DP; McNair, C; Shilkrut, M; Visakorpi, T; Wilder-Romans, K, 2013
)
1.83
"Cyclin D1 is a good and useful marker for the detection of intestinal dysplasia."( Assessment of Cryptosporidium parvum infection in immunocompetent and immunocompromised mice and its role in triggering intestinal dysplasia.
Abdou, AG; Afifi, AF; Elnaidany, NF; Harba, NM, 2013
)
1.11
"Cyclin D1 (CCND1) is an important cell-cycle regulator involved in carcinogenesis and progression of prostate cancer. "( Prognostic significance of cyclin D1 polymorphisms on prostate-specific antigen recurrence after radical prostatectomy.
Bao, BY; Huang, CH; Huang, CN; Huang, CY; Huang, SP; Lin, VC; Liu, CC; Pu, YS; Wang, JS; Wu, TT; Yu, CC, 2013
)
2.13
"Cyclin D1 (CCND1) is a key regulatory protein of the cell cycle. "( Cyclin D1 polymorphism in non-small cell lung cancer in a Portuguese population.
Araújo, A; Catarino, R; Coelho, A; Gomes, M; Lopes, C; Medeiros, R; Nogueira, A, 2012
)
3.26
"Cyclin D1 is an oncogene that encodes a key regulator of the cell cycle, while MEN1 is a tumor suppressor gene that has also been implicated in familial multiple endocrine neoplasia type 1 (MEN1), in which primary HPT is common."( Molecular basis of hyperparathyroidism and potential targets for drug development.
Arnold, A; Krebs, LJ, 2002
)
1.04
"Cyclin D1 is a proto-oncogene that is overexpressed in many cancers including breast and prostate. "( Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation.
Aggarwal, BB; Banerjee, S; Liu, M; Mukhopadhyay, A; Stafford, LJ; Xia, C, 2002
)
1.98
"Cyclin D1 is an oncogene that regulates progression through the G(1) phase of the cell cycle. "( Transcription factor IID recruitment and Sp1 activation. Dual function of TAF1 in cyclin D1 transcription.
Hilton, TL; Wang, EH, 2003
)
1.99
"Cyclin D1 is a proto-oncogene that functions by inactivation of the retinoblastoma tumor suppressor protein, RB. "( Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.
Conti, CJ; Fox, SR; Giesting, S; Knudsen, ES; Lambeck, TC; Lan, Z; Senderowicz, AM; Solomon, DA; Wang, Y, 2003
)
3.2
"Cyclin D1 functions as a strong AR corepressor by directly interacting with and inhibiting receptor activity."( Specificity of cyclin D1 for androgen receptor regulation.
Burd, CJ; Cook, SL; Knudsen, KE; Marshall, TW; Petre-Draviam, CE; Wetherill, YB, 2003
)
1.39
"Cyclin D1 is an oncogenic cyclin frequently over-expressed in cancer. "( Beta-catenin/Tcf-1-mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone.
Kashiwabara, Y; Kitagawa, M; Masuda, H; Matsushita, A; Misawa, H; Nagayama, K; Nakamura, H; Nakano, K; Natsume, H; Nishiyama, K; Sasaki, S, 2003
)
2.02
"Cyclin D1 is a nuclear protein that plays an important role in regulating the cell cycle by promoting entry of cells from the G1 to S phase."( Immunohistochemical expression of glucose transporter Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes.
Aletra, C; Batistatou, A; Kourounis, G; Ladopoulos, J; Ravazoula, P; Tzigounis, B, 2003
)
1.28
"Cyclin D1 is a key protein involved in cell cycle regulation. "( Cyclin D1 gene polymorphism and familial prostate cancer: the AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage.
Koike, H; Nakata, S; Ohtake, N; Satoh, T; Suzuki, K; Takei, T; Yamanaka, H,
)
3.02
"Cyclin D1 is a target molecule transcriptionally activated by aberrant beta-catenin in Wnt signalling, while prolyl isomerase Pin1 promotes cyclin D1 overexpression directly or through accumulation of beta-catenin in cancer cells. "( Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant beta-catenin expression.
Abrosimov, A; Ito, M; Kondo, H; Lushnikov, E; Meirmanov, S; Nakashima, M; Namba, H; Naruke, Y; Rogounovitch, T; Roumiantsev, P; Saenko, V; Sekine, I; Shimizu-Yoshida, Y; Takamura, N; Tsyb, A; Yamashita, S, 2004
)
3.21
"Cyclin D1 is a positive-regulator of the cell cycle and is overexpressed in myeloma cells with t(11;14)(q13;q32). "( Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
Asaoku, H; Imanaka, F; Katayama, Y; Kimura, A; Masuda, R; Nakaju, N; Okikawa, Y; Otsuki, T; Oue, N; Sakai, A; Sasaki, A; Takimoto, Y; Tsujimoto, T; Yasui, W, 2004
)
3.21
"Cyclin D1 is a key cell cycle regulator protein with demonstrated oncogenenic activity in a variety of malignancies. "( Cyclin D and cisplatin cytotoxicity in primary neuroblastoma cell lines.
Berg, S; Blaney, S; Burlingame, S; Nuchtern, JG; Plon, SE; Rousseau, R; Zhang, L, 2004
)
1.77
"Cyclin D1 is a key cell-cycle regulatory protein required for the cell to progress through G1 to S phase. "( Evaluation of cyclin D1 expression and its subcellular distribution in mouse tissues.
Cavallotti, I; Cottone, G; De Falco, M; De Luca, A; De Luca, L; Fedele, V; Laforgia, V; Penta, R, 2004
)
2.13
"Cyclin D1 is a positive cell cycle regulator that is overexpressed in a variety of neoplasms, including mantle cell lymphoma and breast carcinoma."( Expression profile and molecular genetic regulation of cyclin D1 expression in epithelioid sarcoma.
Bergfeld, WF; Fisher, C; Goldblum, JR; Hartke, M; Hicks, D; Lin, L; Montgomery, E; Sigel, JE; Tubbs, R; Xu, B, 2005
)
1.3
"Cyclin D1 (CCND1) is a key cell cycle regulatory protein that governs cell cycle progression from the G(1) to S phase. "( Association of cyclin D1 genotype with breast cancer risk and survival.
Cai, H; Cai, Q; Cheng, J; Gao, YT; Moore, DB; Pierce, L; Shu, XO; Wen, W; Zheng, W, 2005
)
2.12
"Cyclin D1 is a key regulatory protein for the transition of cells from the G(1)-S cell cycle phase."( Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract.
Buch, S; Davis, AG; Grandis, JR; Odom, D; Romkes, M; Siegfried, JM; Zhu, B, 2005
)
1.32
"Cyclin D1 is postulated to be a target of the canonical Wnt pathway and critical for intestinal adenoma development. "( Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine.
Clarke, AR; Clevers, H; Muncan, V; Reed, KR; Sansom, OJ; van de Wetering, M; Winton, DJ, 2005
)
3.21
"Cyclin D1 (CCND1) is an important positive regulator of the G1/S phase of the cell cycle."( Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism.
Catarino, R; Craveiro, R; Lopes, C; Matos, A; Medeiros, R; Pereira, D; Pinto, D; Vasconcelos, A, 2005
)
1.3
"Cyclin D1 is a target molecule transcriptionally activated by aberrant beta-catenin in Wnt signalling. "( Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression.
Abrosimov, A; Ito, M; Kondo, H; Lantsov, D; Lushnikov, E; Meirmanov, S; Nakashima, M; Namba, H; Naruke, Y; Saenko, V; Sekine, I; Yamashita, Sh, 2005
)
3.21
"Cyclin D1 is a key protein involved in cell cycle regulation. "( Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.
Han, M; Han, ZC; Hou, X; Pang, T; Wang, S; Xu, Z; Zhou, Y; Zhu, X; Zou, Y, 2005
)
3.21
"Cyclin D1 is a critical regulator involved in cell cycle progression through the G1 phase into the S phase, thereby contributing to cell proliferation."( Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells.
Albanese, C; Chinnappan, D; Pestell, R; Weber, HC; Xiao, D, 2005
)
1.38
"Cyclin D1 (CCND1) is a set of periodic regulatory proteins that is believed to govern cell cycle transit from G1 into S phase. "( Cyclin D1 protein tissue detection in laryngeal cancer.
Ferekidis, EA; Kavantzas, NG; Lazaris, AC; Lendari, IE; Nikolopoulos, TP; Patsouris, ES; Segas, JV; Tzagkaroulakis, AM, 2005
)
3.21
"Cyclin D1 is a multifunctional protein that activates CDK4 and CDK6, titrates Cip/Kip CDK inhibitors to increase CDK2 activity, and modulates the function of certain transcription factors. "( Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.
Hinds, PW; Landis, MW; Li, T; Pawlyk, BS; Sicinski, P, 2006
)
3.22
"Cyclin D1 is a multifaceted regulator of both transcription and cell-cycle progression that exists in two distinct isoforms, cyclin D1a and D1b. "( Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.
Burd, CJ; Fenoglio-Preiser, CM; Haiman, CA; Knudsen, ES; Knudsen, KE; Li, J; Lu, S; Morey, LM; Petre, CE; Revelo, MP; Wang, Y; Wong, J, 2006
)
3.22
"Cyclin D1 is an important regulator of G1-S phase cell cycle transition and has been shown to be important for breast cancer development. "( Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.
Alao, JP; Coombes, RC; Lam, EW; Stavropoulou, AV; Vigushin, DM, 2006
)
2.01
"Cyclin D1 is a regulatory protein involved in the cell cycle of both normal and neoplastic cells. "( Impact of the cyclin D1 A870G polymorphism on susceptibility to sporadic colorectal cancer in Taiwan.
Changchien, CR; Chen, JS; Chiang, JM; Hsieh, LL; Huang, WS; Lin, PY; Tang, R; Wang, JY; Yeh, CY, 2006
)
2.14
"Cyclin D1 is a key regulator of cell proliferation, acting as a mitogen sensor and linking extracellular signaling to the cell cycle machinery. "( Protein kinase C alpha signaling inhibits cyclin D1 translation in intestinal epithelial cells.
Black, AR; Black, JD; Hizli, AA; Pysz, MA, 2006
)
2.04
"Cyclin D1 acts as a growth factor sensor in G1 phase and is overexpressed in many breast cancer tumors."( Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1.
Danilenko, M; Levy, J; Nahum, A; Prall, OW; Sharoni, Y; Sutherland, RL; Watts, CK; Zeller, L, 2006
)
1.28
"Cyclin D1 gene (CCND1) is a key regulator of the G(1) phase of the cell cycle."( Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions.
Gu, J; Huang, M; Lee, JJ; Lin, J; Lippman, SM; Spitz, MR; Wu, X, 2006
)
2.5
"Cyclin D1 is a highly regulated mediator of the cell cycle and is frequently overexpressed in sporadic PETs."( Clinicopathologic and immunohistochemical correlation in sporadic pancreatic endocrine tumors: possible roles of utrophin and cyclin D1 in malignant progression.
Chang, MC; Nosé, V; Xiao, S, 2007
)
1.27
"Cyclin D1 is a critical regulator of androgen-dependent transcription and cell cycle progression in prostate cancer cells. "( Impact of differential cyclin D1 expression and localisation in prostate cancer.
Buncher, CR; Comstock, CE; Knudsen, KE; Revelo, MP, 2007
)
2.09
"Cyclin D1 is an important regulator of cell cycle progression and can function as a transcriptionl co-regulator. "( The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention.
Alao, JP, 2007
)
2.12
"Cyclin D1 is an important regulator of the early phase of the cell cycle and the transcriptional machinery. "( Alternative cyclin D1 forms a and b have different biological functions in the cell cycle of B lymphocytes.
Lévêque, C; Marsaud, V; Renoir, JM; Sola, B, 2007
)
2.16
"Cyclin D1 is a multifunctional, tumor-associated protein that interacts with pRb via a conserved LxCxE motif, activates a kinase partner, directs the phosphorylation of pRb, activates cyclin E-cyclin-dependent kinase 2 (cdk2) by titrating Cip/Kip cdk inhibitors, and modulates the activity of a variety of transcription factors. "( The LxCxE pRb interaction domain of cyclin D1 is dispensable for murine development.
Baker, GL; Brown, NE; Das, M; Geng, Y; Hinds, PW; Landis, MW; Shifrin, A; Sicinski, P, 2007
)
2.06
"The cyclin D1 gene (CCND1) is a proto-oncogene playing a critical role in the transition through the G1 to the S phase of the cell cycle and is overexpressed in many tumors. "( Altered cyclin D1 genotype distribution in human sporadic pituitary adenomas.
Cagatay, P; Ciplak, N; Erensoy, N; Ersoy, IH; Gazioglu, NM; Hatirnaz, O; Kadioglu, P; Kisacik, B; Oz, B; Ozbek, U; Sar, M; Sayitoglu, MA, 2007
)
1.33
"Cyclin D1 is a major downstream target of both c-erbB2 and ER."( Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee, A; Lee, KY; Lee, MA; Park, G; Park, WC; Yim, HW, 2007
)
1.37
"Cyclin D1 is a proto-oncogene that is overexpressed in many cancers and plays a role in cell proliferation through activation by beta-catenin signaling."( Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells.
Baek, SJ; Cekanova, M; Lee, SH, 2008
)
1.07
"Cyclin D1 is an essential regulator of the G1 phase of the cell cycle progression and plays an important role in the transition of the cell from the G1 phase to the S phase of the cell cycle. "( CCND1 polymorphisms (A870G and C1722G) modulate its protein expression and survival in oral carcinoma.
Abraham, T; Kannan, S; Nalinakumari, KR; Sathyan, KM, 2008
)
1.79
"Cyclin D1 is an important cell cycle regulator, but in cancer its overexpression also increases cellular migration mediated by p27 KIP1 stabilization and RhoA inhibition. "( Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration.
Casimiro, MC; Jiao, X; Katiyar, S; Li, Z; Pestell, RG; Powell, MJ; Prendergast, GC; Wang, C, 2008
)
2.19
"The cyclin D1 gene is a collaborative oncogene overexpressed in greater than 50% of human breast cancers."( Inhibition of cyclin D1 gene transcription by Brg-1.
Casimiro, MC; D'Amico, M; Engel, DA; Leader, JE; Lisanti, MP; Liu, M; Murphy, DJ; Pestell, RG; Rao, M; Shirley, LA; Stallcup, M; Wang, C, 2008
)
1.19
"Cyclin D1 expression is an independent poor prognostic factor in women with early-stage, hormone receptor-positive breast cancer who received adjuvant tamoxifen-based therapy."( Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Dietze, O; Filipits, M; Gnant, MF; Greil, R; Grill, R; Huynh, A; Jakesz, R; Kwasny, W; Lax, S; Lehnert, M; Rudas, M; Schippinger, W; Singer, C; Stierer, M; Stiglbauer, W, 2008
)
3.23
"Cyclin D1 is an important regulator of G1/S phase cell cycle progression, and it is known to play a role in myocyte differentiation in cultured cells."( Nerve Growth factor regulation of cyclin D1 in PC12 cells through a p21RAS extracellular signal-regulated kinase pathway requires cooperative interactions between Sp1 and nuclear factor-kappaB.
Casimiro, MC; Ciccarelli, C; Fu, M; Lee, RJ; Lindsay, J; Marampon, F; Pestell, RG; Popov, VM; Powell, MJ; Watanabe, G; Zani, BM, 2008
)
1.35
"Cyclin D1 is an important nuclear protein required for progression of cells through the G1 phase of the cell cycle. "( Cyclin D1 immunoreactivity in meningiomas.
Berisavac, I; Berisavac, II; Djuricic, S; Jovanovic, MB; Marinkovic, T; Milenković, S, 2008
)
3.23
"Cyclin D1 is a key regulator of cell proliferation. "( Cyclin D1 mediates resistance to apoptosis through upregulation of molecular chaperones and consequent redistribution of cell death regulators.
Colomer, D; Lincet, H; Pichereau, V; Roué, G; Sola, B, 2008
)
3.23
"Cyclin D1/PRAD1 (bcl-1) is a recently discovered proto-oncogene that is overexpressed in mantle cell lymphomas and several other human tumors. "( Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry.
Arnold, A; Harris, NL; Yang, WI; Zukerberg, LR, 1995
)
3.18
"Cyclin D1/PRAD1 is a likely "driver" gene for this amplicon because of its role in cell cycle control and because it has been specifically implicated as an oncogene in parathyroid adenomas and B-cell lymphomas with 11q13 translocation breakpoints."( Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene.
Arnold, A; Gadd, M; Koerner, FC; Schmidt, EV; Thor, AD; Yang, WI; Zukerberg, LR, 1995
)
2.46
"Cyclin D1 is a cell cycle regulator essential for G1 phase progression and a candidate proto-oncogene whose deregulated expression has been implicated in pathogenesis of several types of cancer. "( Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis.
Bartek, J; Bartkova, J; Lukas, J; Strauss, M, 1995
)
3.18
"Cyclin D1 is a key regulator of the G1 phase of the cell cycle. "( Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts.
Draetta, GF; Pagano, M; Tam, SW; Theodoras, AM, 1994
)
3.17
"Cyclin D1 is a nuclear phosphoprotein that is thought to play a major role in the control of G0/G1-->S progression. "( Protein kinase A phosphorylates cyclin D1 at three distinct sites within the cyclin box and at the C-terminus.
Müller, R; Sewing, A, 1994
)
2.01
"Cyclin D1 is a cell-cycle regulator essential for G1 phase progression and a candidate proto-oncogene implicated in pathogenesis of several human tumour types, including breast carcinomas. "( Cyclin D1 protein expression and function in human breast cancer.
Bartek, J; Bartkova, J; Lukas, J; Lützhøft, D; Müller, H; Strauss, M, 1994
)
3.17
"Cyclin D1 is a G1-specific cyclin that has been linked to lymphoid, parathyroid, and breast tumors. "( Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E.
Lazaris-Karatzas, A; Rosenwald, IB; Schmidt, EV; Sonenberg, N, 1993
)
2.06
"The cyclin D1 gene is a single copy gene within the zebrafish genome, which undergoes an alternative polyadenylation process."( Zebrafish cyclin D1 is differentially expressed during early embryogenesis.
Geiger, B; Salomon, D; Yarden, A, 1995
)
1.17
"Cyclin D1 is a key regulator of the G1-S transition in cell cycle, and its gene is amplified and overexpressed in many cancers. "( Tumorigenicity and gene amplification potentials of cyclin D1-overexpressing NIH3T3 cells.
Asano, K; Kakizoe, T; Machida, T; Ochiya, T; Ohishi, Y; Sakamoto, H; Sasaki, H; Sugimura, T; Terada, M; Yoshida, T, 1995
)
1.98
"Cyclin D1 is a G1 cyclin that participates in the control of the cell cycle progression by interacting with the retinoblastoma gene product (pRb)."( Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity.
Bosch, F; Campo, E; Cardesa, A; Fernandez, PL; Jares, P; Mallofré, C; Miquel, R; Montserrat, E; Nayach, I; Perez-Losada, A; Pinyol, M; Piris, MA; Sanchez-Beato, M; Soler, F, 1996
)
1.24
"Cyclin D1 is a cell-cycle regulatory protein essential for G1-S transition and has been identified as a potential transforming gene affected by the translocation."( bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma.
Bartek, J; Dürr, A; Fischer, L; Helbing, A; Kreipe, H; Müller-Hermelink, HK; Ott, G; Ott, MM, 1996
)
1.32
"Cyclin D1 is a cell-cycle regulator and candidate proto-oncogene implicated in the pathogenesis of numerous tumor types. "( Amplification and expression of the cyclin D1 gene in anal and esophageal squamous cell carcinomas.
Davis, B; Fenoglio-Preiser, CM; Heffelfinger, S; Miller, MA; Noffsinger, AE; Sheyn, I, 1997
)
2.01
"Cyclin D1 is a major positive regulator of the G1 restriction point promoting inactivation of the retinoblastoma protein (RB). "( Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression.
Barbareschi, M; Barbazza, R; Bevilacqua, G; Buttitta, F; Caffo, O; Dalla Palma, P; Marchetti, A; Pellegrini, S; Pelosio, P, 1997
)
1.74
"Cyclin D1 is a cell cycle regulator of G1 progression that has been suggested to play a relevant role in the pathogenesis of several human cancer types. "( Expression of cyclin D1 correlates with malignancy in human ovarian tumours.
Alama, A; Barbieri, F; Cagnoli, M; Foglia, G; Pedullà, F; Ragni, N, 1997
)
2.1
"Cyclin D1 is a cell cycle regulator essential for G1 phase progression and is frequently overexpressed in several human tumour types as a consequence of gene amplification or chromosomal rearrangements. "( Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers.
Kim, WS; Kong, G; Lee, JD; Lee, TY; Shin, KY; Woo, YN, 1997
)
2.07
"Cyclin D1 is a critical oncogene involved in the regulation of progression through the G1 phase of the cell cycle, thereby contributing to cell proliferation. "( Transforming growth factor-alpha enhances cyclin D1 transcription through the binding of early growth response protein to a cis-regulatory element in the cyclin D1 promoter.
Lee, MH; Nakagawa, H; Rustgi, AK; Yan, YX, 1997
)
2
"Cyclin D1 is a cell-cycle regulator essential for G1 phase progression and a candidate proto-oncogene implicated in pathogenesis of several human tumor types including esophageal cancers. "( Amplification and overexpression of cyclin D1 in aggressive human esophageal cancer.
Adachi, Y; Inomata, M; Kitano, S; Shiraishi, N; Tanimura, H; Uchino, S,
)
1.85
"Cyclin D1 is a target for positive regulation by estrogens in growth-responsive cells, in which it mediates their mitogenic effects. "( Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens.
Addeo, R; Altucci, L; Bresciani, F; Cancemi, M; Cicatiello, L; Germano, D; Lallemand, F; Michalides, RJ; Pacilio, C; Petrizzi, VB; Salzano, S; Weisz, A, 1998
)
2.03
"Cyclin D1 is a protein derived from the PRAD1, CCND1 or bcl-1 gene on chromosome 11q13, which is involved in both normal regulation of the cell cycle and neoplasia."( Cyclin D1 and human neoplasia.
Chetty, R; Donnellan, R, 1998
)
2.46
"Cyclin D1 is an important regulator of the G1 phase of the cell cycle. "( Increased cyclin D1 expression in chronic pancreatitis.
Arber, N; Beger, HG; Ishiwata, T; Korc, M; Kornmann, M, 1998
)
2.15
"Cyclin D1 is a cell-cycle regulating protein known to be overexpressed in a proportion of bladder carcinomas."( Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer.
Ackermann, D; Alund, G; Gasser, TC; Jordan, P; Knönagel, H; Luginbühl, T; Maurer, R; Mihatsch, MJ; Moch, H; Rist, M; Sauter, G; Schmid, U; Süess, K; Wagner, U; Zellweger, T, 1999
)
2.47
"Cyclin D1 is a cell cycle regulator which is overexpressed in a variety of human cancers. "( Expression of the cyclin D1 gene in rat colorectal aberrant crypt foci and tumors induced by azoxymethane.
Esumi, H; Fukushima, S; Otori, K; Sugiyama, K, 1999
)
2.08
"Cyclin D1 is a key cell cycle regulatory protein with demonstrated oncogenic activity in a variety of malignancies. "( Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
Blamey, RW; Gee, JM; Hui, R; Kenny, FS; Musgrove, EA; Nicholson, RI; Robertson, JF; Sutherland, RL, 1999
)
2.08
"Cyclin D1 is a key regulator of the G1 phase progression of the cell cycle. "( Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone.
Cordon-Cardo, C; Drobnjak, M; Fazzari, M; Osman, I; Scher, HI, 2000
)
2.08
"Cyclin D1 is a key regulatory protein of G1 progressing of cell cycle of mesangial cells, and the cellular proliferation stimulated by Endothelin-1 can be suppressed prominently in antisense Cyclin D1 gene transducted mesangial cells."( [Antisense to cyclin D1 inhibits the proliferation of glomerular mesangial cells].
Huang, H; Lu, Y; Wang, H, 1998
)
2.1
"Cyclin D1 is a critical component of the core cell cycle machinery. "( A specific role for cyclin D1 in mammary gland development.
Sicinski, P; Weinberg, RA, 1997
)
2.06
"Cyclin D1 is a G1 cyclin that controls the transition of the cell cycle from G1 phase to S phase, and its gene is located on chromosome 11q13. "( Evaluation of cyclin D1 mRNA expression in gastric and colorectal cancers.
Kataoka, M; Oda, K; Okabayashi, T; Orita, K; Shibuya, Y; Takeda, A; Tanaka, N, 1999
)
2.11
"Cyclin D1 is a cell cycle regulatory protein, which acts as a growth factor sensor to integrate extracellular signals with the cell cycle machinery, particularly during G1 phase of the cell cycle. "( Molecular cloning and sequence analysis of the promoter region of mouse cyclin D1 gene: implication in phorbol ester-induced tumour promotion.
Eto, I, 2000
)
1.98
"Cyclin D1 is a key cell cycle regulatory protein, the expression and subcellular localization of which is often altered in human tumor cells. "( Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative.
Cassidy, J; Curran, S; Douglas, JJ; McKay, JA; McLeod, HL; Murray, GI; Ross, VG, 2000
)
3.19
"Cyclin D1 is a G1 cyclin participating in the control of cell cycle progression through interaction with the retinoblastoma gene product (pRB). "( Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index.
Baldanzi, A; Basolo, F; Caligo, MA; Fedeli, F; Fontanini, G; Iacconi, P; Miccoli, P; Pacini, F; Pinchera, A, 2000
)
3.19
"Cyclin D1 is a protein that works during the G1-phase of the cell cycle."( Proliferation markers, proliferating cell nuclear antigen, Ki67, 5-bromo-2'-deoxyuridine, and cyclin D1 in mouse olfactory epithelium.
Ichimura, K; Ohta, Y, 2000
)
1.25
"Cyclin D1 is a set of periodic protein which governs G1 progression. "( [Overexpression of cyclin D1 in laryngeal carcinomas].
Tan, S; Zhong, R; Zhou, W, 1998
)
2.07
"Cyclin D1 is a regulatory factor essential in the progression of the cell cycle from G1 through S phase. "( Third place--Resident Research Competition, AAO-2000. Antisense cyclin D1 inhibits growth of head and neck cancer xenografts in nude mice.
Lee, NJ; Mintz, LE; Natarajan, V; Srivatsan, ES; Wang, MB; Wang, SJ, 2001
)
1.99
"Cyclin D1 is a cell cycle regulatory factor that modulates a critical step in cell cycle control. "( Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin.
Srivatsan, ES; Wang, MB; Yip, HT, 2001
)
2.16
"Cyclin D1 is a cell-cycle regulator essential for G1 phases progression and a candidate proto-oncogene implicated in the pathogenesis of several human tumor types."( Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer.
Ishida, T; Saitoh, G; Sugimachi, K; Sugio, K,
)
1.13
"Cyclin D1 is an important regulator of the transition from G1 into S phase of the cell cycle. "( A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT.
Dow, R; Ganiatsas, S; Germain, D; Schulman, B; Thompson, A, 2001
)
1.98
"Cyclin D1 is a known oncogene and a key regulator of cell cycle progression. "( Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice.
Aramandla, R; Beauchamp, RD; Deane, NG; Diehl, L; Lee, WJ; Nanney, LB; Parker, MA; Shyr, Y; Washington, MK, 2001
)
2.01
"As cyclin D1 is a critical determinant of RB phosphorylation and cell cycle progression, we probed the pathway through which cyclin D1 degradation occurs in response to DNA damage."( DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2.
Baskaran, R; Edelmann, W; Knudsen, ES; Lan, Z; Leone, G; Park, CH; Sever-Chroneos, Z; Strobeck, MW, 2002
)
1.09
"Cyclin D1 is a key regulator of G1-to-S phase progression of the cell cycle."( Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression.
Guan, JL; Pestell, R; Zhao, J, 2001
)
1.32
"Cyclin D1 is a major regulator of the progression of cells into the proliferative stage of the cell cycle."( p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells.
Fujiwara, T; Katsuda, K; Shao, J; Tanaka, N; Teraishi, F, 2002
)
1.29
"Cyclin D1 is a critical gene involved in the regulation of progression through the G(1) phase of the cell cycle, thereby contributing to cell proliferation. "( Enhanced skin carcinogenesis in cyclin D1-conditional transgenic mice: cyclin D1 alters keratinocyte response to calcium-induced terminal differentiation.
Hirai, K; Ochiya, T; Saito, I; Sakamoto, H; Sasaki, H; Takeshita, F; Terada, M; Toriyama-Baba, H; Yamamoto, H; Yoshida, T, 2002
)
2.04
"Cyclin D1 expression is a common event in MM patients (50%) and is associated either with a t(11;14)(q13;q32) or extra copies of chromosome 11. "( Cyclin D1 expression in patients with multiple myeloma.
Avet-Loiseau, H; Macro, M; Malet, M; Mellerin, MP; Roussel, M; Sola, B; Troussard, X, 2000
)
3.19
"Cyclin D1 is a key cell cycle regulator and a candidate proto-oncogene, whose deregulation has been implicated in pathogenesis of several types of cancers, including NPC. "( Cyclin D1 polymorphism and the susceptibility to NPC using DHPLC.
Cao, Y; Deng, L; Deng, XY; Lü, YY; Pan, KF; Wang, Y; Zhao, XR, 2002
)
3.2

Effects

Cyclin D1 gene (CCND1) has a G to A polymorphism at the splice donor site of exon 4, position 870. It has a half-life of only ~30 min as a result of its ubiquitylation and proteasomal degradation.

Cyclin D1 (CCND1) has been identified as a metastatic promoter in various tumors including lung adenocarcinoma (LUAD), a subtype of non small cell lung cancer (NSCLC) Cyclin D 1 expression has been reported in a subset of patients with diffuse large B-cell leukemia.

ExcerptReferenceRelevance
"Cyclin D1 has a central role in cell cycle control and is an important component of estrogen regulation of cell cycle progression. "( High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.
Ahlin, C; Blomqvist, C; Embretsén-Varro, E; Fjällskog, M-; Jirström, K; Lundgren, C, 2017
)
2.23
"Cyclin D1 gene (CCND1) has a G to A polymorphism at the splice donor site of exon 4, position 870. "( Lack of evidence for predictive and prognostic value of cyclin D1 gene polymorphism CCND1 G870A for oral squamous cell carcinoma.
Assaf, AT; Atac, A; Blessmann, M; Friedrich, RE; Gröbe, A; Heiland, M; Izbicki, JR; Kluwe, L; Riecke, B, 2014
)
2.09
"Cyclin D1 has a higher expression in breast cancer, positively correlated with ER and better prognosis."( [High expression of cyclin D1 is correlated with the expression of estrogen receptor and good prognosis in breast cancer].
Chen, Y; Nan, K; Qin, S; Yang, C; Zhang, Y, 2016
)
2.2
"Cyclin D1 has a half-life of only ~30 min as a result of its ubiquitylation and proteasomal degradation, with various F-box proteins, including Fbxo4, Fbxw8, Skp2, and Fbxo31, having been found to contribute to its ubiquitylation."( Genetic reevaluation of the role of F-box proteins in cyclin D1 degradation.
Kanie, T; Matsumoto, A; Matsumoto, M; Nakatsumi, H; Nakayama, KI; Onoyama, I; Tateishi, Y; Tsunematsu, R; Yamada, M; Yamamura, S, 2012
)
1.35
"Cyclin D1 has been shown to participate in the pathogenesis of breast cancer. "( Identification of expression of CCND1-related lncRNAs in breast cancer.
Ghafouri-Fard, S; Hidayat, HJ; Hussen, BM, 2022
)
2.16
"Cyclin D1 has been recognized as an oncogene since it was upregulated in several different types of cancers."( Multiple cullin-associated E3 ligases regulate cyclin D1 protein stability.
Chen, D; Lu, K; Tong, L; Wei, G; Xiao, G; Zhang, M, 2023
)
1.89
"Cyclin D1 (CCND1) has been revealed as a key regulating protein in cell cycle (G1 phase) and plays a critical role in promoting tumor development. "( Differential Expression and Prognostic Value of Cytoplasmic and Nuclear Cyclin D1 in Prostate Cancer.
Cao, Z; Chen, X; Guo, F; He, J; Ji, J; Sun, Y; Wang, F; Xu, H; Xu, Y, 2020
)
2.23
"Cyclin D1 (CCND1) has been identified as a metastatic promoter in various tumors including lung adenocarcinoma (LUAD), a subtype of non small cell lung cancer (NSCLC). "( CCT5 interacts with cyclin D1 promoting lung adenocarcinoma cell migration and invasion.
He, J; Hu, Y; Luo, H; Luo, K; Luo, Q; Meng, Y; Tao, X; Wei, X; Xu, Q; Yang, L; Yu, G; Zheng, X, 2021
)
2.39
"Cyclin D1 expression has been reported in a subset of patients with diffuse large B-cell leukemia (DLBCL), but studies have been few and generally small, and they have demonstrated no obvious clinical implications attributable to cyclin D1 expression."( Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Bhagat, G; Dybkaer, K; Farnen, JP; Han van Krieken, J; Hsi, ED; Medeiros, LJ; Montes-Moreno, S; Møller, MB; O'Malley, DP; Ok, CY; Orazi, A; Piris, MA; Ponzoni, M; Richards, KL; Tzankov, A; Visco, C; Winter, JN; Xu-Monette, ZY; Young, KH; Zu, Y, 2014
)
2.11
"Cyclin D1 polymorphism has been reported to be associated with risk of breast cancer, but the published studies have yielded controversial results. "( Genetic association between cyclin D1 polymorphism and breast cancer susceptibility.
Huo, X; Kang, X; Li, W; Li, X; Wang, Y; Yang, Q, 2014
)
2.14
"Cyclin D1 has been reported overexpressed in many malignant cancers. "( Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression.
Cheng, G; Dong, C; Lv, W; Wang, Y; Zhang, J; Zhang, L, 2015
)
2.19
"The Cyclin D1 protein has been extensively studied over the last decades, for its various roles in physiological processes, both in normal and cancer cells. "( No difference in CCND1 gene expression between breast cancer patients with and without lymph node metastasis in a Southern Brazilian sample.
Breginski, FS; Cavalcanti, TC; de Souza, RL; Maia, LB; Ribeiro, EM; Roxo, VM, 2016
)
0.99
"Cyclin D1 has been demonstrated to affect the radiation sensitivity in cancer cells."( Inhibition of cyclin D1 enhances sensitivity to radiotherapy and reverses epithelial to mesenchymal transition for esophageal cancer cells.
Chen, X; Fang, Y; Fei, Z; Jin, X; Shen, L; Su, H; Xie, C; Zhang, X, 2016
)
1.52
"Cyclin D1 (CCND1) has been reported to be the 'driver' of this amplicon, however, multiple genes map to the smallest region of amplification of 11q13."( Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study.
Dedes, KJ; Geyer, FC; Lacroix-Triki, M; Lambros, MB; Lopez-Garcia, MA; Natrajan, R; Reis-Filho, JS; Savage, K; Vatcheva, R; Wetterskog, D; Wilkerson, P, 2010
)
1.08
"Cyclin D1 has been strongly implicated in cell proliferation particularly in the G1/S checkpoint of the cell cycle, and prognoses in human malignancies. "( Correlation of cyclin D1 expression with aggressive DNA pattern in patients with tobacco-related intraoral squamous cell carcinoma.
Das, SN; Khare, P; Sharma, SC; Singh, MK, 2011
)
2.16
"Cyclin D1 (CCND1) has been associated with chemotherapy resistance and poor prognosis. "( CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.
Chen, W; Feng, Z; Guo, W; Ji, T; Li, J; Mao, L; Qiu, W; Ren, G; Sun, J; Tu, W; Wang, B; Wang, L; Wang, Z; Xu, Q; Yang, X; Zhang, C; Zhang, P; Zhang, Z; Zhu, H, 2011
)
1.81
"Cyclin D1 has been reported to be associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC)."( CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma.
Fujii, M; Ishiguro, R; Kameyama, K; Ogawa, K; Tashiro, M; Tomita, T; Yamashita, T,
)
1.57
"Cyclin D1 has been identified as an important oncogene and the cdk inhibitors as tumor suppressors in human breast carcinogenesis."( Rho GTPases as key transducers of proliferative signals in g1 cell cycle regulation.
Welsh, CF, 2004
)
1.04
"Cyclin D1 has been implicated in G1 cell cycle progression and is frequently amplified, overtranscribed, and oversynthesized in human tumors, including esophageal carcinomas. "( Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line.
Harris, CC; Jiang, W; Kim, SJ; Okamoto, A; Spillare, EA; Stoner, GD; Weinstein, IB, 1994
)
2.04
"Cyclin D1, a G1 cyclin, has been implicated in the oncogenesis of various types of malignancies via deregulation of cell cycles. "( Cyclin D1 protein expression in lung cancer.
Chung, KY; Kim, YB; Shin, DH; Yang, WI, 1996
)
3.18
"Cyclin D1 has been implicated as a putative protooncogene whereas mutations of the p53 gene occur frequently in invasive transitional cell carcinomas (TCCs) of the urinary bladder."( Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features.
Fukushima, S; Ikemoto, S; Kishimoto, T; Lee, CC; Morimura, K; Nakatani, T; Nishisaka, N; Wada, S; Wanibuchi, H; Yamamoto, S, 1997
)
1.36
"Cyclin D1 has been reported to be overexpressed in many tumours, including breast carcinomas. "( Expression of cyclin Ds in relation to p53 status in human breast carcinomas.
Berner, JM; Bukholm, IK; Børresen-Dale, AL; Nesland, JM, 1998
)
1.74
"Cyclin D1 has been shown to be overexpressed in several cancer types and to act as an oncogene in breast cancers."( Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer.
Armes, J; Germain, D; Hendley, J; Russell, A; Thompson, MA; Trute, L, 1999
)
2.47
"Cyclin D1 and E have been found to be deregulated and overexpressed in various types of cancers. "( Immunohistochemical study on the expression of cyclin D1 and E in gastric cancer.
Aoyagi, K; Koufuji, K; Murakami, N; Shirouzu, K; Takeda, J; Tanaka, M; Terasaki, Y; Yamasaki, Y; Yano, S, 2000
)
2.01
"Cyclin D1 dysregulation has been found with varying frequencies in multiple myeloma (MM) and has been suggested to be associated with a poor prognosis. "( Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma.
Johnsen, HE; Knudsen, LM; Rasmussen, T,
)
1.85

Actions

Cyclin D1 (CCND1) gene plays a significant role in the transition from G1 to S phase of the cell cycle and in the phosphorylation of retinoblastoma tumor suppressor protein. It remains unknown how cyclin D 1 expression is regulated during early embryonic development.

ExcerptReferenceRelevance
"Cyclin D1 plays a critical role in tumorigenesis and the regulation of the G1/S transition in the cell cycle. "( Clinicopathological and prognostic significance of cyclin D1 amplification in patients with breast cancer: a meta-analysis.
An, HX; He, Q; Liu, XL; Ma, YH; Wang, WY; Wu, J; Wu, XT,
)
1.83
"Cyclin D1 expression is lower in control group compared with UIP groups (1.2 vs."( Evaluation of Cyclin D1 as a Discriminatory Immunohistochemical Biomarker for Idiopathic Pulmonary Fibrosis.
Baratelli, FE; Elatre, W; Koss, MN; Wei, CH; Xiao, GQ, 2019
)
1.6
"Cyclin D1 (CCND1) gene plays a significant role in the transition from G1 to S phase of the cell cycle and in the phosphorylation of retinoblastoma tumor suppressor protein."( Relationship between cyclin D1 (A870G) gene polymorphism and lung cancer.
Cakina, S; Gulyasar, T; Kocak, Z; Ozen, A; Sener, S; Sipahi, T, 2013
)
1.43
"Cyclin D1 (CCND1) promotes cell cycle by inhibiting retinoblastoma protein (RB1)."( Insulin like growth factor 2 regulation of aryl hydrocarbon receptor in MCF-7 breast cancer cells.
Salisbury, TB; Tomblin, JK, 2014
)
1.12
"Cyclin D1 (CCND1) plays a significant role in G1-S transition of cell cycle, and phosphatase and a tensin homologue (PTEN) negatively regulate cell cycle through phosphatidylinositol 3-kinase (PI3K)/AKT signaling. "( Genetic polymorphisms of CCND1 and PTEN in progression of esophageal squamous carcinoma.
Chen, ZP; Jang, Y; Lu, SA; Ma, J; Wang, JJ; Xu, CQ; Zhang, CZ, 2013
)
1.83
"Cyclin D1 plays an important role in the regulation of cellular proliferation and its expression is activated during gastrulation in the mouse; however, it remains unknown how cyclin D1 expression is regulated during early embryonic development. "( GCNF-dependent activation of cyclin D1 expression via repression of Mir302a during ESC differentiation.
Archer, TK; Cooney, AJ; Wang, H; Wang, X; Zwaka, TP, 2014
)
2.14
"Cyclin D1 plays a vital role in cancer cell cycle progression and is overexpressed in many human cancers, including colorectal cancer (CRC). "( Prognostic significance of cyclin D1 expression in colorectal cancer: a meta-analysis of observational studies.
Li, Y; Wei, J; Xu, C; You, T; Zhao, Z, 2014
)
2.14
"Cyclin D1 (CCND1) plays a key role in cell cycle regulation. "( Cyclin D1 G870A polymorphism and risk of nasopharyngeal carcinoma: a case-control study and meta-analysis.
Chen, H; Ding, C; He, Z; Huang, GL; Li, B; Liao, D; Luo, S; Pu, X; Wu, Y, 2014
)
3.29
"Cyclin D1 (CCND1) plays essential roles in cancer progression. "( Prognostic value of differential CCND1 expression in patients with resected gastric adenocarcinoma.
Huang, Q; Lan, F; Liu, W; Ma, L; Ouyang, X; Wang, X; Xie, F; Yu, Y, 2015
)
1.86
"Cyclin D1 plays a vital role in cell cycle arrest, which is induced by let-7b overexpression."( Let-7b overexpression leads to increased radiosensitivity of uveal melanoma cells.
Dai, L; Fan, J; Fan, X; Ge, S; Jia, R; Song, X; Xu, X; Zhang, L; Zhou, Y; Zhuang, A, 2015
)
1.14
"Cyclin D1 promotes the cell cycle by inhibiting retinoblastoma protein (RB1)."( Keratinocyte Growth Factor Regulation of Aryl Hydrocarbon Receptor Activation in Colorectal Cancer Cells.
Han, B; Pu, A; Sheng, B; Sun, L; Wang, Q; Yang, H; Yang, K; Yin, J, 2016
)
1.16
"Cyclin D1 promotes cell cycle progression during G1 phase, a key event in G1-S transition. "( An update on the implications of cyclin D1 in oral carcinogenesis.
Ayén, A; Gil-Montoya, JA; González-Moles, MA; González-Ruiz, L; Navarro-Triviño, FJ; Ramos-García, P; Scully, C, 2017
)
2.18
"Cyclin D1 (CCND1) plays an essential role in regulating the progress of the cell cycle from G1 to S phase. "( Association of CCND1 Gene c.870G>A Polymorphism with Breast Cancer Risk: A Case-ControlStudy and a Meta-Analysis.
Aftabi, Y; Karimian, M; Kheirkhah, D; Sharif, A; Sharif, MR; Soleimani, Z, 2017
)
1.9
"Cyclin D1 plays a pivotal role in cell-cycle transition through G1 phase. "( Overexpression of degenerative spermatocyte homolog 1 up-regulates the expression of cyclin D1 and enhances metastatic efficiency in esophageal carcinoma Eca109 cells.
Chen, HX; Ji, XD; Sun, ZJ; Xie, D; Ye, XL; Zhou, W, 2009
)
2.02
"Cyclin D1 protein plays an important part in regulating the progress of the cell during the G(1) phase of the cell cycle. "( Breast cancer and cyclin D1 gene polymorphism in Turkish women.
Arikan, S; Ergen, A; Görmüs, U; Isbir, T; Küçücük, S; Sahin, O; Yaylim-Eraltan, I; Yigit, N; Yildiz, Y,
)
1.91
"The cyclin D1 activation plays a critical role in MCL pathogenesis but additional oncogenic events, such as aberrations of the ARF/MDM2/p53 pathway are also necessary for progression of the disease."( Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma.
Fabian, P; Falkova, I; Malcikova, J; Moulis, M; Muzik, J; Ravcukova, B; Slovackova, J; Smardova, J; Stefancikova, L; Vasova, I, 2010
)
0.84
"Cyclin D1b promotes tumorigenesis through the stimulation of angiogenesis."( Cyclin K and cyclin D1b are oncogenic in myeloma cells.
Andrieux, G; Dembele, D; Jost, B; Liu, JM; Marsaud, V; Renoir, JM; Sola, B; Tchakarska, G; Wdzieczak-Bakala, J, 2010
)
1.45
"Cyclin D1 plays important roles in esophageal squamous cell carcinoma (ESCC) cases by amplification of the 11q13.3 locus. "( FBXO31 determines poor prognosis in esophageal squamous cell carcinoma.
Kogo, R; Komune, S; Mimori, K; Mori, M; Tanaka, F, 2011
)
1.81
"Cyclin D1 gene (CCND1) plays pivotal roles in the development of several human cancers, including breast cancer, functioning as an oncogene. "( Age dependent switching role of cyclin D1 in breast cancer.
Amato, A; Caparello, B; D'Angelo, R; Leotta, A; Lio, S; Malara, NM; Mollace, V; Rinaldi, C; Ruggeri, A; Sidoti, A, 2012
)
2.11
"Cyclin D1 (CCND1) plays a vital role in cancer cell cycle progression. "( Cyclin D1 G870A polymorphism contributes to colorectal cancer susceptibility: evidence from a systematic review of 22 case-control studies.
Ma, Y; Qin, H; Shi, C; Wang, F; Yang, Y; Zou, Y, 2012
)
3.26
"Cyclin D1 plays significant roles in cell cycle entry and migration. "( Cyclin D1 expression in podocytes: regulated by mitogens in collaboration with integrin-extracellular matrix interaction through extracellular signal-regulated kinase.
Chang, JM; Chen, CA; Chen, HC; Cheng, YC; Guh, JY; Hwang, JC, 2012
)
3.26
"Cyclin D1 (CCND1) plays an essential role in tumor development and progression through regulating the cell transition from G1 to the proliferative S phase. "( Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis involving 23,998 subjects.
Du, Q; Gao, M; Liu, H; Lu, S; Tang, SC; Yang, J, 2011
)
3.25
"Cyclin D1 (CCND1) plays a critical role in the G1 to S-phase cell cycle transition. "( Cyclin D1 polymorphism and oral cancer: a meta-analysis.
Cao, X; Ge, L; Gu, H; Lin, B; Wang, W; Yang, J; Zhao, Y, 2013
)
3.28
"Cyclin D1 plays a key role in cell cycle control, particularly in the transition from G1 to S phase, regulated by cyclin-dependent kinases. "( Significance of cyclin D1 polymorphisms in patients with head and neck cancer.
Baig, RM; Kayani, MA; Mahjabeen, I; Sabir, M, 2013
)
2.18
"Cyclin D1 is known to activate CDK4, which then phosphorylates the RB protein, leading to cell cycle progression."( The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer.
Bloigu, R; Haapasaari, KM; Jukkola-Vuorinen, A; Koivunen, P; Peurala, E, 2013
)
1.38
"Cyclin D1 plays an important role in the multi-step process of gastrointestinal tumorigenesis. "( Oncogenic transformation of normal enterocytes by overexpression of cyclin D1.
Arber, N; Deutsch, V; Dvory-Sobol, H; Kazanov, D; Kolker, O; Kunik, T; Liberman, E; Pick, M; Shapira, I; Strier, L, 2003
)
2
"Cyclin D1 plays an important role in the regulation of G1 progression of the somatic cell cycle by functioning as a regulatory subunit of cdk4 and 6. "( In vivo analysis of the cyclin D1 promoter during early embryogenesis in Xenopus.
Kato, JY; Kubota, M; Shinohara, K; Tanaka, T; Yasuda, K, 2003
)
2.07
"Cyclin D1 ASODN could inhibit the growth and the expression of Cyclin D1 mRNA in gastric carcinoma cells, influence the cell cycle and expression of its regulators."( Effects of cyclin D1 antisense oligodeoxyneucleotides on the growth and expression of G1 phase regulators in gastric carcinoma cells.
Han, G; Shuai, X; Wang, G, 2003
)
1.43
"Cyclin D1 gene (CCND1) plays a key role in the control of the cell cycle, and its amplification is described in numerous cancers."( [CCND1 gene amplification in the adenoid cystic carcinoma of the minor salivary glands].
García Pedrero, J; García-Carracedo, D; González Meana, MV; Rodrigo Tapia, JP; Sequeiros Santiago, G; Suárez Nieto, C, 2004
)
1.04
"Cyclin D1 plays a critical role in cell proliferation and tumor progression."( Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding.
Colburn, NH; Hu, J, 2005
)
1.31
"Cyclin D1 plays an important role in the regulation of the G1 phase in the cell cycle. "( Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance.
Ahnström, M; Nordenskjöld, B; Rutqvist, LE; Skoog, L; Stål, O, 2005
)
2.21
"Cyclin D1 gene plays an important role in progression of RCCC by stimulating cell proliferation."( [Correlation of cyclin D1 overexpression to mutations of von hippel-lindau gene in renal clear cell carcinoma].
Du, LJ; Feng, ZQ; Leng, J; Ren, YY, 2006
)
1.4
"Cyclin D1 (CCND1) plays a key role in cell cycle control, particularly in the transition from G1 to S phase, which is regulated by cyclin-dependent kinases. "( Cyclin D1 A870G polymorphism and the risk of colorectal cancer and adenoma.
Chan, AT; Colditz, GA; Fuchs, CS; Giovannucci, E; Hunter, DJ; Ma, J; Schernhammer, ES; Tranah, GJ; Willett, WC, 2006
)
3.22
"Cyclin D1 ASODN could increase the chemosensitivity to 5-FU, MTX, CDDP in cells."( Cyclin D1 antisense oligodexoyneucleotides inhibits growth and enhances chemosensitivity in gastric carcinoma cells.
Chen, JH; Han, GX; Shuai, XM; Wang, GB, 2006
)
2.5
"Cyclin D1 promotes cellular motility through inhibiting ROCK signaling and repressing the metastasis suppressor TSP-1."( Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling.
Burbelo, P; Dai, M; Dye, C; Fu, M; Jiao, X; Ju, X; Li, A; Li, Z; Lu, Y; Pestell, RG; Quong, AA; Stanley, ER; Wang, C; Yang, J; Zhang, X, 2006
)
2.5
"Cyclin D1 promotes nuclear DNA synthesis through phosphorylation and inactivation of the pRb tumor suppressor. "( Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function.
Du, R; Fu, M; Katiyar, S; Leader, JE; Li, Z; Lu, Y; Novikoff, PM; Pestell, RG; Quong, A; Wang, C; Yang, J, 2006
)
3.22
"Cyclin D1 plays an important role in cell cycle progression. "( BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR.
ElShamy, WM; Hao, L, 2007
)
2.1
"Cyclin D1 plays an important role in regulating the progression of cells through the G1-phase of the cell cycle. "( Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the penis.
Anagnostakis, D; Betsi, E; Fangoulis, M; Frangoulis, M; Kouvatseas, G; Kouvidou, Ch; Papadopoulos, O; Tsakistou, G,
)
1.93
"Cyclin D1 plays a critical role in controlling the G(1)/S transition via the regulation of cyclin-dependent kinase activity. "( PKR and PKR-like endoplasmic reticulum kinase induce the proteasome-dependent degradation of cyclin D1 via a mechanism requiring eukaryotic initiation factor 2alpha phosphorylation.
Baltzis, D; Gao, HQ; Koromilas, AE; Mounir, Z; Papadakis, AI; Raven, JF; Wang, S, 2008
)
2.01
"Cyclin D1 plays a key regulatory role during the G1 phase of the cell cycle and its gene is amplified and over-expressed in many cancers. "( Identification of the cyclin D1b mRNA variant in mouse.
Bollig, A; Liao, DJ; Thakur, A; Wu, J; Wu, SH, 2009
)
2.11
"Cyclin D1 plays a critical role in the timing of the initiation of DNA synthesis in the normal cell cycle of mammalian cells. "( Determination of the prognostic value of cyclin D1 overexpression in breast cancer.
Anderson, JJ; Angus, B; Henry, JA; Horne, CH; Lennard, TW; McIntosh, GG; Milton, I; Parr, AH; Steward, M; Thomas, MD, 1995
)
2
"Cyclin D1 can also activate the adenovirus E2 promoter via E2F."( Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1.
Henglein, B; Jansen-Dürr, P; Schulze, A; Spitkovsky, D; Zerfass, K, 1994
)
1.27
"Cyclin D1 plays a pivotal role in G1, and this gene is frequently amplified and overexpressed in several types of human cancer."( Overexpression of cyclin D1 enhances gene amplification.
Jiang, W; Weghorst, CM; Weinstein, IB; Zhou, P, 1996
)
1.35
"Cyclin D1 plays an important role in regulating the progression of cells through the G1 phase of the cell cycle. "( Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells.
Arber, N; Delohery, T; Doki, Y; Han, EK; Holt, PR; Kim, NH; Klein, MG; Sgambato, A; Weinstein, IB; Zhou, P, 1997
)
2.11
"Cyclin D1 plays a key regulatory role during the G1 phase of the cell cycle and its gene is amplified and overexpressed in many cancers. "( Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression.
Hiyama, H; Iavarone, A; LaBaer, J; Reeves, SA, 1997
)
2.02
"Cyclin D1 levels increase significantly while the levels of cyclin E, cdk2, and the p21 and p27 cdk inhibitors are relatively constant."( Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
Planas-Silva, MD; Weinberg, RA, 1997
)
1.02
"Cyclin D1 plays an important role in control of the cell cycle, and overexpression of PRAD1/cyclin D1 may be involved in disease progression in these cases."( Overexpression of PRAD1/cyclin D1 in plasma cell leukemia with t(11;14)(q13;q32).
Araki, S; Ashihara, E; Fujita, N; Goto, H; Hirai, H; Inaba, T; Kikuta, T; Nakagawa, M; Shimazaki, C; Suzuki, R; Takahashi, R; Tatsumi, T; Yamagata, N, 1997
)
1.33
"Cyclin D1 plays an important role in the development of breast cancer and is required for normal breast cell proliferation and differentiation associated with pregnancy. "( Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.
Brown, M; DiRenzo, J; Dowdy, SF; Ewen, ME; Hinds, PW; Ladha, MH; Lin, N; Miller, SJ; Neuman, E; Pestell, RG; Upton, TM, 1997
)
3.18
"Cyclin D1 plays a key role in the regulation of the G1/S transition through the cell cycle. "( Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas.
al-Sedairy, ST; Farid, NR; Shi, Y; Zou, M, 1998
)
2.04
"Cyclin D1 plays a critical role in regulating cell-cycle progression. "( Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma.
Hartwick, W; Kandel, R; Rohan, T; Zhu, XL, 1998
)
3.19
"Cyclin D1 plays an important role in cell cycle progression from G1 to S phase. "( Cyclin D1 expression in renal carcinomas and oncocytomas: an immunohistochemical study.
Amin, MB; Brynes, RK; Gelb, AB; Lin, BT; McCourty, A; Medeiros, LJ, 1998
)
3.19
"Cyclin D1 protein plays an important part in regulating the progress of the cell during the G1 phase of the cell cycle. "( Cyclin D1 in breast cancer.
Barnes, DM; Gillett, CE, 1998
)
3.19
"Cyclin D1 plays an important role in the regulation of cell progression through G1 of the cell cycle and has been demonstrated to have oncogenic properties. "( Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors.
Bicknell, JE; Broome, JC; Clayton, RN; Farrell, WE; Hibberts, NA; Hoban, PR; Simpson, DJ, 1999
)
2.13
"Cyclin D1 plays an essential regulatory role in the G1 phase of the cell cycle. "( Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas.
Cheffetz, S; Herlyn, M; Klein-Szanto, AJ; Litwin, S; Nesbit, M; Sauter, ER, 1999
)
2.15

Toxicity

ExcerptReferenceRelevance
" No deleterious systemic adverse effects were apparent."( Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats.
Furlani, D; Gäbel, R; Klopsch, C; Li, W; Ma, N; Steinhoff, G; Ugurlucan, M; Yerebakan, C, 2009
)
0.35
" In fact, although available data are somehow conflicting, there is evidence that MTBE is a toxic substance that may have harmful effects on both animals and humans and an unresolved problem is the role played by MTBE metabolites, especially tertiary butyl alcohol (TBA), in determining toxic effects due to MTBE exposure."( Differential toxic effects of methyl tertiary butyl ether and tert-butanol on rat fibroblasts in vitro.
Bergamaschi, A; Bianchino, G; Boninsegna, A; Cittadini, A; De Paola, B; Iavicoli, I; Pietroiusti, A; Sgambato, A, 2009
)
0.35
" Liver regeneration is a vital process for survival after a toxic insult."( Ringer's lactate improves liver recovery in a murine model of acetaminophen toxicity.
Kajander, H; Koskinen, ML; Tenhunen, J; Yang, R; Zhang, S; Zhu, S, 2011
)
0.37
" In a group of 184 RA patients treated with MTX, we have investigated whether selected polymorphisms in these genes modulate MTX efficacy and/or have impact on adverse drug effects (ADEs)."( Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients.
Bunjevacki, V; Damjanov, N; Damnjanovic, T; Jekic, B; Kovacevic, L; Krajinovic, M; Lukovic, L; Maksimovic, N; Milasin, J; Milic, V; Novakovic, I; Popovic, B; Radunovic, G, 2013
)
0.39
" All adverse drug events were recorded."( Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients.
Bunjevacki, V; Damjanov, N; Damnjanovic, T; Jekic, B; Kovacevic, L; Krajinovic, M; Lukovic, L; Maksimovic, N; Milasin, J; Milic, V; Novakovic, I; Popovic, B; Radunovic, G, 2013
)
0.39
"The purpose of this study was to investigate the association between single nucleotide polymorphism (SNP) of CCND1 A870G and acute adverse events (AEs) in postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy (CRT)."( [Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
DU, ZL; Huang, Y; Jin, J; Li, YX; Lin, DX; Qiao, Y; Ren, H; Tan, W; Yu, DK, 2013
)
0.39
"The differences in drug efficacy and adverse reactions may be caused by genetic variations in drug metabolism between individuals."( Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis.
Karpiński, P; Noga, L; Pawłowska, J; Ślęzak, R; Świerkot, J; Szechiński, J; Wiland, P, 2015
)
0.42
"A total of 273 Caucasian patients with RA were treated with MTX for at least 6 months or stopped MTX because of adverse effects."( Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis.
Karpiński, P; Noga, L; Pawłowska, J; Ślęzak, R; Świerkot, J; Szechiński, J; Wiland, P, 2015
)
0.42
"Of all patients, 53% reported some adverse effects during at least 1 visit, which led to MTX withdrawal in 17% of the patients."( Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis.
Karpiński, P; Noga, L; Pawłowska, J; Ślęzak, R; Świerkot, J; Szechiński, J; Wiland, P, 2015
)
0.42
"The MTHFR 677CC and GGH 401TT and CT genotypes were associated with a reduction in the number of MTX-related adverse events."( Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis.
Karpiński, P; Noga, L; Pawłowska, J; Ślęzak, R; Świerkot, J; Szechiński, J; Wiland, P, 2015
)
0.42
"Of the 13 patients, 11 experienced disease progression, 1 patient was withdrawn because of an adverse event (AE), and 1 patient died."( A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Advani, S; Cassaday, RD; Chawla, P; Gandhi, M; Gopal, AK; Goy, A; Nachankar, R, 2015
)
0.42
" The nuclear receptor pregnane X receptor (PXR; NR1I2) is a broad-specificity sensor with species-specific responses to toxic agents."( Pregnane X Receptor-Humanized Mice Recapitulate Gender Differences in Ethanol Metabolism but Not Hepatotoxicity.
Gonzalez, FJ; Gyamfi, AA; Gyamfi, MA; Richardson, RM; Spruiell, K; Yeyeodu, ST, 2015
)
0.42
"The importance of evaluating the toxic effects associated with the use of reclaimed water has been increasing."( Toxicity study of reclaimed water on human embryonic kidney cells.
Chae, KJ; Kim, T; Kou, YY; Ng, HY; Ren, X, 2017
)
0.46
" The aim of this study was to investigate the mechanism by which folic acid can inhibit the toxic effects of BaP both in vivo and in vitro."( The intervention mechanism of folic acid for benzo(a)pyrene toxic effects in vitro and in vivo.
Chen, Y; Gong, Z; Wang, L; Wang, P; Wu, Y, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacodynamic effects of seliciclib, a cyclin-dependent kinase (CDK) inhibitor, were studied in patients with nasopharyngeal carcinoma."( Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer.
Chiao, J; Cui, CY; Dong, D; Goh, BC; Green, S; Hsieh, WS; Lai, YF; Lee, SC; Loh, T; Mow, B; Peh, BK; Salto-Tellez, M; Soh, D; Soo, R; Soong, R; Wong, LS, 2009
)
0.35
"Brief treatment with this regimen of seliciclib in patients with nasopharyngeal carcinoma is tolerable at 400 mg bd and associated with tumor pharmacodynamic changes consistent with cdk inhibition, and warrants further efficacy studies in this tumor."( Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer.
Chiao, J; Cui, CY; Dong, D; Goh, BC; Green, S; Hsieh, WS; Lai, YF; Lee, SC; Loh, T; Mow, B; Peh, BK; Salto-Tellez, M; Soh, D; Soo, R; Soong, R; Wong, LS, 2009
)
0.35

Compound-Compound Interactions

The study was conducted to evaluate the prognostic significance of cyclin D1 and retinoblastoma (Rb) expression in combination with abnormal p53 accumulation in primary, resected non-small cell lung cancers.

ExcerptReferenceRelevance
"This study was conducted to evaluate the prognostic significance of cyclin D1 and retinoblastoma (Rb) expression in combination with abnormal p53 accumulation in primary, resected non-small cell lung cancers (NSCLCs)."( Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers.
Ariyoshi, Y; Koshikawa, T; Kuroishi, T; Mitsudomi, T; Nagatake, M; Nishio, M; Sugiura, T; Suyama, M; Takahashi, T; Yatabe, Y, 1997
)
0.83
" We now extend these findings by evaluating the effect on preformed melanomas of (1) intratumoral therapy with wt p53 alone, (2) wt p53 in combination with antisense (AS) CD1, both short (< or =14 days) and longer term, and (3) doubling the dose or repeat doses of wt p53 or AS CD1."( p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma.
Herlyn, M; Litwin, S; Sauter, ER; Takemoto, R, 2002
)
0.58
" These findings demonstrate that siRNA silencing of either eIF4E or CCND1 leads to inhibition of the growth of HNSCC cells and suggest that these siRNAs alone or combined with conventional cytotoxic agents may be useful for therapy of HNSCCs."( Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin.
Kim, HJ; Lotan, R; Oridate, N; Xu, X, 2005
)
0.54
" We therefore investigated the efficacy of the farnesyltransferase inhibitor (FTI) R115777 (tipifarnib) in combination with tamoxifen in MCF-7 human breast cancer models both in vitro and in vivo."( The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Detre, S; Dowsett, M; Head, JE; Howes, A; Johnston, SR; Kaye, S; Martin, LA; Pancholi, S; Quinn, E; Salter, J, 2007
)
0.34
"The rats that received celecoxib in combination with exisulind at low doses showed a significant decrease in prostatic intraepithelial neoplasia and adenocarcinomas as well as an enhanced rate of apoptosis."( Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
Bosland, MC; Horton, L; Narayanan, BA; Narayanan, NK; Nargi, D; Randolph, C; Reddy, BS, 2007
)
0.55
" The objective of this study was to analyze the effect of fulvestrant alone or in combination with different steroids in human breast cancer cells in vitro, and to demonstrate whether these steroids will compromise the efficacy of fulvestrant in ER-positive breast cancer cells."( Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Brinkhuis, M; Franke, HR; Jansen, GH; Vermes, I; Wolbers, F, 2008
)
0.35
"We performed experiments in vitro with various hormone therapy preparations (estradiol (E2), dihydrodydrogesterone (DHD) and tibolone) at a concentration of 10(-6) mol/l alone or combined with fulvestrant in different breast cancer cell lines, ER-positive and ER-negative."( Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Brinkhuis, M; Franke, HR; Jansen, GH; Vermes, I; Wolbers, F, 2008
)
0.35
"This in vitro study revealed clear differences in results when various hormone therapy preparations, alone or combined with fulvestrant, are added to ER-positive and ER-negative breast cancer cell lines."( Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Brinkhuis, M; Franke, HR; Jansen, GH; Vermes, I; Wolbers, F, 2008
)
0.35
"Our study demonstrated that fulvestrant, an ER antagonist used in the treatment of ER-positive breast cancer, combined with E2 and DHD or in combination with tibolone, is not compromised in its efficacy in inducing apoptosis in ER-positive breast cancer cell lines in vitro."( Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Brinkhuis, M; Franke, HR; Jansen, GH; Vermes, I; Wolbers, F, 2008
)
0.35
"To demonstrate the antiproliferative and pro-apoptotic activity of the novel pyrazolopyrimidine derivative multiple tyrosine kinase inhibitor CLM3, alone and in combination with SN-38 (the active metabolite of irinotecan), on endothelial and tumor cells and to show its mechanism of action."( Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells.
Antonelli, A; Berti, P; Bocci, G; Canu, B; Cosconati, S; Da Settimo, F; Danesi, R; Di Desidero, T; Fioravanti, A; Frati, R; La Motta, C; Miccoli, P; Mugnaini, L; Orlandi, P; Sartini, S, 2011
)
0.37
"Proliferation and apoptotic assays were performed on microvascular endothelial (HMVEC-d) and lung (A549) and thyroid cancer (8305C, TT) cell lines exposed to CLM3 and to the simultaneous combination with SN38 for 72h."( Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells.
Antonelli, A; Berti, P; Bocci, G; Canu, B; Cosconati, S; Da Settimo, F; Danesi, R; Di Desidero, T; Fioravanti, A; Frati, R; La Motta, C; Miccoli, P; Mugnaini, L; Orlandi, P; Sartini, S, 2011
)
0.37
"The pyrazolopyrimidine derivative CLM3 demonstrated a highly significant and promising antiproliferative and proapoptotic activity, alone and in combination with SN-38, for activated endothelial and cancer cells."( Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells.
Antonelli, A; Berti, P; Bocci, G; Canu, B; Cosconati, S; Da Settimo, F; Danesi, R; Di Desidero, T; Fioravanti, A; Frati, R; La Motta, C; Miccoli, P; Mugnaini, L; Orlandi, P; Sartini, S, 2011
)
0.37
"This study was aimed to investigate the effect of curcumin in combination with bortezomib on the proliferation and apoptosis of human MM cell line H929 in vitro, and to explore its mechanisms."( [Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism].
Bai, QX; Chen, JJ; Huang, GS; Yang, LJ; Zhang, XY; Zhao, H, 2011
)
0.37
"The present study was designed to investigate the effects of cyclooxygenase (COX) inhibitors in combination with taxol on the expression of cyclin D1 and Ki-67 in human ovarian SKOV-3 carcinoma cells xenograft-bearing mice."( Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma.
Cai, JH; Li, W; Tang, YX; Wan, L; Zhang, J, 2012
)
0.81
"Our findings suggest that GDC-0941, either alone or in combination with rapamycin, may serve as a new, promising approach for breast cancer treatment."( The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
Yao, J; Zheng, J; Zou, X, 2012
)
0.38
" The present studies were directed to determine the inhibitory effects of carotenoids in combination with rosiglitazone, a synthetic PPARγ agonist, on K562 cell proliferation and elucidate the contribution of PPARγ-dependent pathway to cell proliferation suppression."( PPARγ-dependent pathway in the growth-inhibitory effects of K562 cells by carotenoids in combination with rosiglitazone.
Gu, H; Li, JH; Zhang, H; Zhao, H; Zhao, WE, 2014
)
0.4
"Carotenoids in combination with rosiglitazone are hopeful to provide attractive dietary or supplementation-based and pharmaceutical strategies to treat cancer diseases."( PPARγ-dependent pathway in the growth-inhibitory effects of K562 cells by carotenoids in combination with rosiglitazone.
Gu, H; Li, JH; Zhang, H; Zhao, H; Zhao, WE, 2014
)
0.4
" In addition, the MHCCLM3 cells were less sensitive to 5-FU when administrated in combination with sorafenib, as evidenced by the half inhibitory concentration (IC50) significantly increasing from (102."( [Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism].
Deng, LF; Jia, QA; Li, JH; Ren, ZG; Shen, HJ; Sun, XJ; Wang, YH, 2013
)
0.39
" The anticancer mechanism of the drug combination was revealed."( Molecular mechanism of inhibitory effects of C-phycocyanin combined with all-trans-retinoic acid on the growth of HeLa cells in vitro.
Chu, XM; Li, B; Lv, CY; Xu, YJ; Yang, F; Yang, P, 2014
)
0.4
" In this study the polyphenol flavonoid quercetin (Q) or sodium butyrate (B) suppressed human esophageal 9706 cancer cell growth in dose dependent manner, and Q combined with B (Q+B) could further inhibit Eca9706 cell proliferation than that induced by Q or B alone, compared with untreated control group (C) in MTT assay."( Aberrant epigenetic alteration in Eca9706 cells modulated by nanoliposomal quercetin combined with butyrate mediated via epigenetic-NF-κB signaling.
Wang, JL; Wu, JL; Yang, SL; Zheng, NG, 2014
)
0.4
" Apoptotic effects of liposomal quercetin (LQ, with cytomembrane-philia) combined with CD133 antiserum were also detected by CD133 immunocytochemistry combined with TUNEL assay."( Anti-CSC effects in human esophageal squamous cell carcinomas and Eca109/9706 cells induced by nanoliposomal quercetin alone or combined with CD 133 antiserum.
Li, JP; Mo, SJ; Wu, JL; Zheng, NG, 2014
)
0.4
" We aimed to assess the safety and efficacy of palbociclib in combination with letrozole as first-line treatment of patients with advanced, oestrogen receptor-positive, HER2-negative breast cancer."( The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Boer, K; Bondarenko, IM; Crown, JP; Ettl, J; Finn, RS; Fowst, C; Huang, X; Kim, ST; Kulyk, SO; Lang, I; Patel, R; Pinter, T; Randolph, S; Schmidt, M; Shparyk, Y; Slamon, DJ; Thummala, AR; Voytko, NL, 2015
)
0.42
" We investigated the efficacy of the histone deacetylase (HDAC) inhibitor vorinostat combined with one of several B-cell receptor (BCR) signaling inhibitors on MCL cell death and the underlying mechanisms, using MCL cell lines."( The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.
Hagiwara, K; Iida, H; Kunishima, S; Miyata, Y; Nagai, H; Naoe, T, 2015
)
0.42
" Metformin combined with aspirin significantly inhibited the phosphorylation of mTOR and STAT3, and induced apoptosis as measured by caspase-3 and PARP cleavage."( Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2.
Carpizo, D; DiPaola, RS; Huang, H; Lin, Y; Tan, XL; Xu, Q; Yang, CS; Yue, W; Zheng, X, 2015
)
0.42
"Objective To investigate the effect of insulin in combination with selenium on p38-mitogen-activated protein kinase/CREB-binding protein (p38MAPK/CBP) pathway in rats with diabetic cardiomyopathy."( [Insulin combined with selenium inhibit p38MAPK/CBP pathway and suppresses cardiomyocyte apoptosis in rats with diabetic cardiomyopathy].
Deng, Y; Li, P; Liu, Y; Meng, J; Xu, T; Xu, X; Zeng, J, 2016
)
0.43
"Objective To investigate the effect and molecular mechanism of β-lapachone combined with NVP-BEZ235 on the proliferation and migration of BGC-823 human gastric cancer cells."( [β-Lapachone combined with NVP-BEZ235 inhibit proliferation and migration of BGC-823 gastric cancer cells].
Chen, L; Cui, X; Lin, Z; Sun, J; Wang, Y, 2018
)
0.48
"The present study aims to investigate the effects of ginsenoside Rg3 combined with oxaliplatin on the proliferation and apoptosis of hepatocellular carcinoma cells and the related mechanism."( Ginsenoside Rg3 Combined with Oxaliplatin Inhibits the Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells via Downregulating PCNA and Cyclin D1.
Hua, H; Qin, S; Shan, K; Shao, J; Wang, Y; Yang, A, 2019
)
0.71
" Using the CCK-8 and Colony formation assay, the anti-proliferation effect of 5-FU combined with Huaier was observed."( The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells.
Che, C; Dong, B; Dong, C; Fu, Z; Liang, R; Ma, K; Wang, H; Wang, X; Zhang, R; Zhao, C, 2019
)
0.51
"Huaier combined with 5-FU exhibited a synergistic anti-tumor effect in Huh28 cell."( The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells.
Che, C; Dong, B; Dong, C; Fu, Z; Liang, R; Ma, K; Wang, H; Wang, X; Zhang, R; Zhao, C, 2019
)
0.51
"To investigate the therapeutic effects of Jiazhu decoction (JZD) in combination with cyclophosphamide (CTX) on the growth of breast cancer in mice and to explore the possible molecular mechanisms of action."( Effects of Jiazhu decoction in combination with cyclophosphamide on breast cancer in mice.
Guan, H; Hou, S; Hu, Y; Liu, H; Liu, S; Xie, Q; Xie, S; Zhang, C; Zhang, Y, 2019
)
0.51
"Ultrasonic microbubbles in combination with microRNA (miRNAs/miRs) exhibited promising effects on cancer treatments."( miR‑378 in combination with ultrasonic irradiation and SonoVue microbubbles transfection inhibits hepatoma cell growth.
Huang, J; Li, Y; Ma, Q; Wang, J, 2020
)
0.56
" The present study was designed to explore the inhibitory effects of tacrolimus (TAC) combined with mycophenolate mofetil (MMF) on the proliferation of mesangial cells based on the cell cycle."( Evaluation of the inhibitory effect of tacrolimus combined with mycophenolate mofetil on mesangial cell proliferation based on the cell cycle.
Gao, Y; Li, R; Tian, J; Wang, Y; Yang, H; Zhou, X, 2020
)
0.56
"This study aimed to elucidate the effect of bone marrow mesenchymal stem cell (BMSC) transplantation combined with the administration of Lugua polypeptide injection into the knee joint cavity to treat knee osteoarthritis (KOA) in rabbits."( Effect of bone marrow mesenchymal stem cell transplantation combined with lugua polypeptide injection on osteoarthritis in rabbit knee joint.
Du, Q; Huang, H; Huang, W; Xiang, C; Zeng, C; Zhang, P, 2022
)
0.72
"BMSC transplantation combined with Lugua polypeptide injection may improve KOA-related cartilage tissue damage in rabbits."( Effect of bone marrow mesenchymal stem cell transplantation combined with lugua polypeptide injection on osteoarthritis in rabbit knee joint.
Du, Q; Huang, H; Huang, W; Xiang, C; Zeng, C; Zhang, P, 2022
)
0.72
" Based on the different effects of statin members, this study aims to evaluate the effect of two of the most promising lipophilic statins, Simvastatin and Pitavastatin, and their combination with a conventional chemotherapeutic regimen of doxorubicin and cyclophosphamide on breast cancer cells."( Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells.
Dewidar, SA; El Gayar, AM; El-Mesery, M; Hamdy, O; Soliman, MM, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
"Arzoxifene (ARZ) is a selective estrogen receptor (ER) modulator with greater bioavailability than raloxifene which is being developed as treatment for breast cancer."( Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.
A'Hern, R; Detre, S; Dowsett, M; Johnston, SR; Riddler, S; Salter, J, 2003
)
0.32
" BMS-554417 was orally bioavailable and significantly inhibited the growth of IGF1R-Sal tumor xenografts in vivo."( In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Attar, RM; Carboni, JM; Conover, CA; Erlichman, C; Frennesson, DB; Gottardis, M; Haluska, P; Kalli, KR; Kaufmann, SH; Lee, FY; Loegering, DA; Saulnier, MG; Wittman, M, 2006
)
0.33
" However, there is concern about the bioavailability of these agents pertinent to the poor absorption and thereby limiting its clinical use."( Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.
Narayanan, BA; Narayanan, NK; Nargi, D; Randolph, C, 2009
)
0.35
"Poor oral bioavailability limits the use of curcumin and other dietary polyphenols in the prevention and treatment of cancer."( Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention.
Blum, A; Freeman, D; Ma, L; Panyam, J; Shahani, K; Swaminathan, SK, 2010
)
0.36
" We have engineered a polymeric nanoparticle encapsulated curcumin formulation (NanoCurc) that shows remarkably higher systemic bioavailability in plasma and tissues compared with free curcumin upon parenteral administration."( Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.
Bisht, S; Chenna, V; Feldmann, G; Goggins, MG; Hong, SM; Karikari, C; Maitra, A; Mizuma, M; Ottenhof, NA; Pramanik, D; Ravi, R; Rudek, MA; Sharma, R, 2010
)
0.36
"One of the main functions of A Disintegrin and Metalloproteinase 10 (ADAM10) is to regulate the bioavailability of adhesion molecules and ligands to various cellular-signaling receptors."( Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFα/NFκB pathway.
Anand, M; Armanious, H; Belch, A; Gelebart, P; Lai, R, 2011
)
0.37
" The expression of insulin-like growth factor-1 (IGF-1) mRNA in hDPCs was significantly induced upon RF radiation at the specific absorption rate of 10 W/kg, which resulted in increased expression of B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL-2) and cyclin D1 (CCND1) proteins and increased phosphorylation of MAPK1 protein."( Induction of hair growth by insulin-like growth factor-1 in 1,763 MHz radiofrequency-irradiated hair follicle cells.
Cho, AR; Choi, HD; Jeon, SI; Jo, SJ; Kim, KH; Kim, KT; Kwon, OS; Pack, JK; Park, GS; Park, WY; Yoon, SY, 2011
)
0.55
" Finally, UA was detected in serum samples obtained from various mice groups fed with enriched diet in nanogram quantity indicating that it is well absorbed in the GI tract."( Ursolic acid inhibits the initiation, progression of prostate cancer and prolongs the survival of TRAMP mice by modulating pro-inflammatory pathways.
Ho, PC; Hui, KM; Kumar, AP; Lun, CK; Ong, TH; Sethi, G; Shanmugam, MK; Wong, PT, 2012
)
0.38
" However, the bioavailability of GEN is very low in vivo."( Inhibition of proliferation and induction of G1-phase cell-cycle arrest by dFMGEN, a novel genistein derivative, in lung carcinoma A549 cells.
Cao, J; He, Z; Peng, B; Wang, C; Yi, S; Zheng, G, 2013
)
0.39
"Curcumin exhibits growth-suppressive activity against a variety of cancer cells, but low bioavailability prevents its use in chemotherapeutic applications."( Antiproliferative effect of an analog of curcumin bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione in human breast cancer cells.
Kumaravel, M; Rukkumani, R; Sankar, P, 2012
)
0.38
" Its bioavailability is low and raises the possibility that the metabolites of resveratrol have biological effects."( Resveratrol 3-O-D-glucuronide and resveratrol 4'-O-D-glucuronide inhibit colon cancer cell growth: evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest.
Carew, MA; Carrington, S; Meira, LB; Modjtahedi, H; Polycarpou, E; Tyrrell, E, 2013
)
0.59
" Previously, we showed that the selective iNOS inhibitor S,S'-1,4-phenylenebis(1,2-ethanediyl)bis-isothiourea (PBIT) caused significant inhibition of colon carcinogenesis induced by azoxymethane (AOM), although it did not completely abrogate NO production due to the exogenous bioavailability of NO and NO generation by eNOS in tumor tissues."( Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats.
Amin, S; Choi, CI; Desai, D; Janakiram, NB; Mohammed, A; Rao, CV; Ravillah, D; Zhang, Y, 2013
)
0.39
" We further show that kainic-acid treatment activates Notch signaling, which increases the bioavailability of CyclinD1 through Akt/GSK3β pathway, leading to aberrant CCR via activation of CyclinD1-Rb-E2F1 axis."( Notch signaling in response to excitotoxicity induces neurodegeneration via erroneous cell cycle reentry.
Alberi, L; Brai, E; Kaczarowski, M; Liu, S; Marathe, S, 2015
)
0.42
" Our results suggest that syndecan-4 functions as a reservoir for promyostatin regulating the local bioavailability of mature myostatin."( Syndecan-4 influences mammalian myoblast proliferation by modulating myostatin signalling and G1/S transition.
Deak, F; Dux, L; Keller-Pinter, A; Kocsis, T; Ocsovszki, I; Puskas, L; Szabo, K; Szilak, L; Zvara, A, 2018
)
0.48
" Previously, we reported that lonafarnib, an orally bioavailable non-peptide inhibitor targeting farnesyltransferase, synergizes with sorafenib against the growth of HCC cells."( The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
Chen, D; Huang, Y; Lian, Y; Wang, J; Wei, H; Zeng, G, 2019
)
0.76
" The phytochemicals' poor bioavailability and short half-life make them unsuitable as anticancer drugs."( The Effect of Dual Bioactive Compounds Artemisinin and Metformin Co-loaded in PLGA-PEG Nano-particles on Breast Cancer Cell lines: Potential Apoptotic and Anti-proliferative Action.
Dadashpour, M; Hassani, N; Jafari-Gharabaghlou, D; Zarghami, N, 2022
)
0.72
" Furthermore, applying PLGA-PEG NPs could improve the bioavailability of free curcumin and chrysin components and at the same time increases the anti-cancer potential of this compound."( Development of PEGylated PLGA Nanoparticles Co-Loaded with Bioactive Compounds: Potential Anticancer Effect on Breast Cancer Cell Lines.
Jafari-Gharabaghlou, D; Mohammadinejad, S; Zarghami, N, 2022
)
0.72

Dosage Studied

QRT-PCR showed that the target gene cyclin D1 mRNA expression was gradually decreased with the dosage of aspirin. Increased dosage of chromosome 21-localized Dyrk1a steeply increases G1 cell cycle duration.

ExcerptRelevanceReference
" These findings provide the first evidence for the amplification of a cyclin gene in human esophageal cancer and suggest that an increase in cyclin D gene dosage could be an important factor in the pathogenesis of esophageal cancer."( Amplification and expression of the human cyclin D gene in esophageal cancer.
Jiang, W; Kahn, SM; Lu, SH; Tomita, N; Weinstein, IB; Zhang, YJ, 1992
)
0.28
" Increased gene dosage does not seem to be the only mechanism that resulted in increased protein expression as detected by immunohistochemistry."( Immunohistochemistry of cyclin D1 in human breast cancer.
Caamano, J; Cooper, F; Guo, X; Klein-Szanto, AJ; Zhang, SY, 1994
)
0.6
" This was investigated here by taking advantage of an experimental model that reproduces cyclin D1 overexpression resulting from increased CCND1 gene dosage in hormone-responsive human breast cancer cells."( Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens.
Addeo, R; Altucci, L; Bresciani, F; Cancemi, M; Cicatiello, L; Germano, D; Lallemand, F; Michalides, RJ; Pacilio, C; Petrizzi, VB; Salzano, S; Weisz, A, 1998
)
0.81
" The gene dosage of CCND1 was examined in 51 primary laryngeal squamous cell carcinomas, and amplification of the gene was found in 9 (17."( Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications.
Almadori, G; Bellacosa, A; Cadoni, G; Cavallo, S; Ferrandina, G; Galli, J; Neri, G; Scambia, G, 1996
)
1.74
" Treatment of Ms-1 cells with inostamycin, an inhibitor of phoshatidylinositol (PI) synthesis, reduced the dosage of paclitaxel required to induce cell death by apoptosis."( Potentiation of paclitaxel cytotoxicity by inostamycin in human small cell lung carcinoma, Ms-1 cells.
Imoto, M; Simizu, S; Takada, M; Tanabe, K; Tashiro, E; Umezawa, K, 1998
)
0.3
" Thus, a reduction of p21 dosage may promote tumor progression in the presence of other oncogenic initiators."( Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model.
Cui, XS; Donehower, LA; Jones, JM; Medina, D, 1999
)
0.54
" They also received MJ, MJ2, or MJ5 as a drinking water at night for 36 weeks, starting 1 week after the last dosing of AOM."( Suppression of azoxymethane-induced colon carcinogenesis in male F344 rats by mandarin juices rich in beta-cryptoxanthin and hesperidin.
Azuma, Y; Kagami, S; Kohno, H; Murakami, M; Ogawa, H; Shimada, R; Sumida, T; Tanaka, T, 2000
)
0.31
" Increased CCND1 gene dosage is a more sensitive prognostic factor than protein overexpression as evaluated by conventional immunohistochemical techniques."( Image cytometry of cyclin D1: a prognostic marker for head and neck squamous cell carcinomas.
Babb, JS; Klein-Szanto, AJ; Liu, SC; Ridge, JA; Zhang, SY, 2001
)
0.64
" The dosage of cisplatin ranged from 1 microg/mL to 10 microg/mL."( Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin.
Srivatsan, ES; Wang, MB; Yip, HT, 2001
)
0.71
" CCND1 overexpression requires oestrogen receptor integrity and is exacerbated by amplification at 11q13 (the site of the CCND1 gene), owing to an additional gene dosage effect."( Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays.
Bièche, I; Lidereau, R; Noguès, C; Olivi, M; Vidaud, M, 2002
)
0.31
" Hence, unlike IDC, increase in gene dosage did not account for the protein excess."( CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast.
Castresana, JS; Fan, X; Furió-Bacete, V; Klein-Szanto, AJ; López de la Osa, I; Mercapide, J; Patchefsky, AS; Schneider, J; Zhang, SY, 2002
)
0.31
" Fluorescence emitted from each product was used to determine the ratio of expression of cyclin D1 to D2 and D3 by assigning a dosage quotient [D1/(D2+D3)]."( Quantitation of cyclin D1 over-expression using competitive fluorescent reverse transcription polymerase chain reaction: a tool for the differential diagnosis of mantle cell lymphoma.
Armitage, H; Boyce, M; Ellard, S; Jones, DB; Joyner, MV; Sarsfield, P; Wickham, CL; Wilkins, BS, 2003
)
0.89
"The dosage of triptonide was 200 micrograms/(kg."( [Male contraception of triptonide and its function mechanism].
Guo, Y; Hui, L; Liu, X; Wang, L; Ye, W, 2000
)
0.31
" The accumulation of cyclin D3 but not D1 protein could, in some cases, be explained by increased gene dosage since extra copies of chromosome 6 were found."( Deregulation of D-type cyclins in uterine cancers. Cyclin D1/D3 is differentially expressed in cervical cancer.
Forus, A; Holm, R; Skomedal, H,
)
0.38
" These results indicate an effect of gene dosage as an alternative mechanism of cyclin D1 deregulation in MM."( Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels.
Bink, K; Fend, F; Haralambieva, E; Hofler, H; Kluin, PM; Koch, I; Kremer, M; Mandl-Weber, S; Quintanilla-Martinez, L; Schuuring, E; Specht, K; Tomer, R, 2004
)
0.86
" Using RNA interference in prostate cancer cell lines with distinct p27(kip1) gene doses, we show that prostate tumorigenicity depends on levels of p27(kip1) and that the consequences of p27(kip1) gene dosage can be attributed, in part, to altered levels of Cyclin D1."( A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis.
Abate-Shen, C; Banach-Petrosky, W; Borowsky, AD; Cardiff, RD; Gao, H; Kim, M; Lee, H; Lin, Y; Ouyang, X; Shen, MM; Shih, WJ, 2004
)
0.5
"A dosage regimen of 28-200 mg/kg per day MMF had no negative effect on either cytotoxic LAK activity or GVL (as measured by finding of leukemic cells in recipient spleen by PCR or the appearance of clinical leukemia with adoptive transfer)."( Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model.
Hirshfeld, E; Kasir, J; Or, R; Resnick, IB; Shapira, MY; Slavin, S; Weiss, L; Zeira, M, 2005
)
0.33
" HeLa cells were used as a model for cervical cancer in this study, and the effect of electrochemical treatment on these cells was examined in four different dosage groups (5 V + 5 C, 10 V + 5 C, 5 V + 10 C and 10 V + 10 C)."( Characterization of the mechanisms of electrochemotherapy in an in vitro model for human cervical cancer.
Jiang, Z; Li, D; Li, L; Li, QQ; Luan, Y; Reed, E; Tang, B; Zhang, W, 2005
)
0.33
" They also received the experimental diet containing 100 or 500 ppm silymarin for 40 weeks, starting 1 week after the last dosing of DMAB."( Dietary supplementation with silymarin inhibits 3,2'-dimethyl-4-aminobiphenyl-induced prostate carcinogenesis in male F344 rats.
Kohno, H; Sugie, S; Suzuki, R; Tanaka, T; Tsuda, H, 2005
)
0.33
" The percentage of the cells in the G0/G1 phase and the S phase at the dosage of 40 mmol/L were 68."( [Inhibition of proliferation of hepatic stellate cells by taurine is mediated via regulating cell cycle proteins].
Chen, SW; Chen, YX; Li, S; Liu, S; Xie, WF; Zhang, XR, 2005
)
0.33
" Interestingly, two of three tumors that were negative for phosphorylated ERK proteins according to western blot harbored CCND1 amplifications, suggesting that the increased gene dosage of CCND1 may exert effects similar to phosphorylated ERK proteins in cell growth."( Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas.
Fujimoto, A; Goto, Y; Ichii, N; Koga, H; Murata, H; Saida, T; Takata, M; Yamaura, M, 2005
)
0.33
" No gene dosage effect was observed in this study."( Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.
Han, M; Han, ZC; Hou, X; Pang, T; Wang, S; Xu, Z; Zhou, Y; Zhu, X; Zou, Y, 2005
)
1.77
" Dose-response studies showed that the growth inhibition seen at lower concentrations of CDDO correlated with induction of the tumor suppressor gene caveolin-1, which is known to inhibit breast cancer cell growth."( Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells.
Abdelrahim, M; Andreeff, M; Hung, MC; Johansen, M; Konopleva, M; Madden, T; McQueen, T; Munsell, MF; Safe, SH; Shi, YX; Tsao, T; Yu, D; Zhang, W, 2006
)
0.33
" High alpha-tocopherol dosing (100 IU/kg bw) showed a clear antioxidant effect, abolished cell proliferation, and promoted an early and progressive apoptosis, despite vitamin E also enhancing levels of endogenous antioxidants."( Rate of oxidant stress regulates balance between rat gastric mucosa proliferation and apoptosis.
Aranda-Fraustro, A; Contreras-Zentella, M; El-Hafidi, M; Escamilla, JE; Hernández-Muñoz, R; Mendieta-Condado, E; Olguín-Martínez, M, 2006
)
0.33
" Altogether, 18/100 (18%) biBC tumors had increased gene dosage of at least one oncogene."( Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias.
Borresen-Dale, AL; Cornelisse, CJ; Henrich, KO; Imyanitov, EN; Lazareva, YR; Matsko, DE; Schwab, M; Sokolenko, AP; Suspitsin, EN; Togo, AV; Turkevich, EA, 2007
)
0.34
" QRT-PCR showed that the target gene cyclin D1 mRNA expression was gradually decreased with the dosage of aspirin."( Down-regulation of beta-catenin nuclear localization by aspirin correlates with growth inhibition of Jurkat cell line.
Hu, L; Shi, J; Wang, L, 2006
)
0.61
"1%, or 1% 9t,11t-CLA for 4 wk starting 1 wk before the first dosing of AOM."( 9trans,11trans conjugated linoleic acid inhibits the development of azoxymethane-induced colonic aberrant crypt foci in rats.
Beppu, F; Hosokawa, M; Kohno, H; Miyamoto, S; Miyashita, K; Suzuki, R; Tanaka, T; Yasui, Y, 2007
)
0.34
" Synergy is dependent on viral replication; however, it is not dependent on the dosing sequence of TSA and G47Delta, viral genetic alterations, infectivity, or replication kinetics of G47Delta."( Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.
Castelo-Branco, P; Liu, TC; Martuza, RL; Rabkin, SD, 2008
)
0.35
" To test whether Bmi1 is required for Hh-driven medulloblastoma development, we varied Bmi1 gene dosage in transgenic mice expressing an oncogenic Hh effector, SmoA1, driven by a glial fibrillary acidic protein (GFAP) promoter."( Bmi1 is required for Hedgehog pathway-driven medulloblastoma expansion.
Blom, M; Dlugosz, AA; Ellison, DW; Ermilov, AN; Ferris, J; Liu, J; Michael, LE; van Lohuizen, M; Wang, A; Westerman, BA, 2008
)
0.35
" Western Blot and densitometric analyses demonstrated a strong dose-response relationship with regard to p53 and RARE expression within the dose-range of 0-8 microg/ml."( Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide.
Tchounwou, PB; Yedjou, CG, 2009
)
0.61
" Here, we evaluated 50 high-grade dysplasias and low-grade dysplasias that later progressed to cancer for gene dosage aberrations using tiling-path DNA microarrays."( Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias.
Garnis, C; Lam, WL; Poh, CF; Rosin, MP; Tsui, IF; Zhang, L, 2009
)
0.35
" The small molecule lead was not acutely toxic up to 550 mg/kg, and dosing at 10 mg/kg reduced human xenograft tumor volume by about 40%."( Fluorescent epigenetic small molecule induces expression of the tumor suppressor ras-association domain family 1A and inhibits human prostate xenograft.
Banerjee, PP; Brown, ML; Grindrod, SC; Jagadeesh, S; Paige, M; Sheikh, KD; Zhang, L, 2010
)
0.36
"We evaluated the ratio of the CCND1 (11q13) dosage to the dopamine receptor D2 (DRD2; 11q22-23) dosage (C/D ratio) as CCND1 copy number."( Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma.
Deguchi, K; Fujiwara, H; Ichikawa, D; Komatsu, S; Konishi, H; Kosuga, T; Morimura, R; Okamoto, K; Otsuji, E; Shiozaki, A; Takeshita, H; Tsujiura, M, 2010
)
0.36
" Immunofluorescent staining results not only confirmed the above changes, but also showed that β-catenin had translocated into the nucleus gradually with the increased dosage of Curcumin."( Curcumin activates Wnt/β-catenin signaling pathway through inhibiting the activity of GSK-3β in APPswe transfected SY5Y cells.
Li, Y; Shi, XD; Yin, WK; Zhang, X, 2011
)
0.37
" However, a large body of evidence has demonstrated that the effects of mitogenic estrogen signaling exhibit a non-monotonic or biphasic, dose-response curve; estrogen at low concentrations, elicits a mitogenic signaling pathway to stimulate cell proliferation, while at high concentrations, estrogen inhibits cell growth."( Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells.
Ding, L; Kang, LG; Wang, ZY; Zhang, XT, 2012
)
0.38
" Finally, we also found that dFMGEN has a dosage effect in suppressing tumor growth in vivo, and that dFMGEN was well tolerated by animals."( Inhibition of proliferation and induction of G1-phase cell-cycle arrest by dFMGEN, a novel genistein derivative, in lung carcinoma A549 cells.
Cao, J; He, Z; Peng, B; Wang, C; Yi, S; Zheng, G, 2013
)
0.39
" A significant decrease in protein levels of cyclin D1 and CDK-2 was found at high dosage of DEHP (100 μM) after 24h treatment."( Di 2-ethyl hexyl phthalate affects differentiation and matrix mineralization of rat calvarial osteoblasts--in vitro.
Arunakaran, J; Balasubramanian, K; Bhat, FA; Karthikeyan, GD; Karthikeyan, S; Parameswari, S; Ramajayam, G; Senthilkumar, K; Srinivasan, N; Vignesh, RC, 2013
)
0.65
" Here we combine live-cell imaging and single-cell analysis to show that increased dosage of chromosome 21-localized Dyrk1a steeply increases G1 cell cycle duration through direct phosphorylation and degradation of cyclin D1 (CycD1)."( Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle.
Chen, JY; Lin, JR; Meyer, T; Tsai, FC, 2013
)
0.84
" For both cyclins protein levels, the maximum stimulation was present at 10-9M BPA and the effects resembled the "inverted U"-shape, a nonmonotonic dose-response curve reported for the action of xenoestrogens."( Bisphenol A alone or in combination with estradiol modulates cell cycle- and apoptosis-related proteins and genes in MCF7 cells.
Fickova, M; Macho, L; Mlynarcikova, A, 2013
)
0.39
" The gene dosage pattern of the ERBB family and its downstream effectors PI3K and MYC showed particularly strong correlations with clinicopathological data."( A multimarker qPCR platform for the characterisation of endometrial cancer.
Biernat, W; Gulczyński, J; Majewska, H; Supernat, A; Wydra, D; Zaczek, AJ; Łapińska-Szumczyk, S, 2014
)
0.4
"The ratio of the CCND1 (11q13) dosage to the DRD2 (11q22-23) dosage (C/D ratio) as the CCND1 copy number was evaluated."( Clinical impact of predicting CCND1 amplification using plasma DNA in superficial esophageal squamous cell carcinoma.
Fujiwara, H; Hirajima, S; Ichikawa, D; Kawaguchi, T; Komatsu, S; Konishi, H; Kubota, T; Miyamae, M; Okamoto, K; Otsuji, E; Shiozaki, A; Takeshita, H; Yagi, N, 2014
)
0.4
" The dosage of ATRA was reduced when it cooperated with C-PC to reduce the toxicity."( Molecular mechanism of inhibitory effects of C-phycocyanin combined with all-trans-retinoic acid on the growth of HeLa cells in vitro.
Chu, XM; Li, B; Lv, CY; Xu, YJ; Yang, F; Yang, P, 2014
)
0.4
" Dependent on its kinase activity and correlated with the dosage of overexpression, DYRK1A blocked proliferation of SH-SY5Y neuroblastoma cells within 24 h and arrested the cells in G₁ phase."( The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation.
Becker, W; Florencio Ortiz, V; Pasqualon, T; Schumacher, J; Soppa, U; Tejedor, FJ, 2014
)
0.63
" To investigate the antitumor effect of erlotinib at different dosing times and the underlying molecular mechanism via the PI3K/AKT pathway, we established a mouse model of Lewis lung cancer xenografts."( Chronopharmacology and mechanism of antitumor effect of erlotinib in Lewis tumor-bearing mice.
An, F; Li, M; Lin, P; Liu, J; Liu, L; Wang, P; Zhang, B; Zhao, L; Zhuang, X, 2014
)
0.4
" The dosage of ATRA was reduced when it was administered with C-PC together, and the toxicity was reduced as well."( The synergistic antitumor effects of all-trans retinoic acid and C-phycocyanin on the lung cancer A549 cells in vitro and in vivo.
Chu, XM; Gao, MH; Li, B; Lv, CY; Teng, L; Yang, P; Yin, QF, 2015
)
0.42
" A best-fit model demonstrated a dose-response peak at 500 mGy."( Nonlinear ionizing radiation-induced changes in eye lens cell proliferation, cyclin D1 expression and lens shape.
Ainsbury, E; Barnard, S; Bouffler, S; Coster, M; Haines, J; Markiewicz, E; Quinlan, RA; Richards, S; Rothkamm, K; van Geel, O; Wu, W, 2015
)
0.65
" These results indicate that CS-NLC shows enhanced cellular uptake but increased cytotoxicity characteristics over NLC and therefore careful optimization of dosage and loading levels in CS-NLC is needed to allow cancer cell targeting, and for exploiting the potential of these systems in cancer therapy."( Surface modification of nanostructure lipid carrier (NLC) by oleoyl-quaternized-chitosan as a mucoadhesive nanocarrier.
Gonil, P; Iempridee, T; Pimtong, W; Ruktanonchai, UR; Sajomsang, W; Suktham, K; Surassmo, S; Yostawonkul, J, 2017
)
0.46
" Here, we characterized expression profiles of β-AR subtypes and established dose-response curves for the nonselective β-AR agonist isoproterenol (ISO) in the developing mouse ventricular cells."( Effects of β-adrenergic receptor drugs on embryonic ventricular cell proliferation and differentiation and their impact on donor cell transplantation.
Allen, B; Baguma-Nibasheka, M; Chinni, S; Feridooni, T; Hotchkiss, A; Pasumarthi, KBS; Zhang, F, 2017
)
0.46
"Our results showed that non-toxic dosage of wogonin (10, 20 µM) could inhibit cells proliferation and suppress cells cycle progression in MHCC97L and HepG2 cell."( Wogonin inhibits cell cycle progression by activating the glycogen synthase kinase-3 beta in hepatocellular carcinoma.
Almutairi, MM; Hong, M; Li, J; Li, S, 2020
)
0.56
"Primary cultures from human umbilical artery endothelial cells were used in dose-response experiments (0."( Bazedoxifene increases the proliferation of human arterial endothelial cells but does not affect the expression of cyclins A, B, and D1 and of p27
Cano, A; Dudenko, D; García-Pérez, MÁ; Gómez, R; Tarín, JJ, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10,594)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1097 (10.35)18.2507
2000's3907 (36.88)29.6817
2010's4694 (44.31)24.3611
2020's896 (8.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.87 (24.57)
Research Supply Index9.30 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index108.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials70 (0.64%)5.53%
Reviews447 (4.11%)6.00%
Case Studies231 (2.12%)4.05%
Observational12 (0.11%)0.25%
Other10,125 (93.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]